Skip to content

Advertisement

BMC Systems Biology

What do you think about BMC? Take part in

Open Access

Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells

BMC Systems BiologyBMC series – open, inclusive and trusted201711:65

https://doi.org/10.1186/s12918-017-0439-8

Received: 3 November 2016

Accepted: 9 June 2017

Published: 28 June 2017

Abstract

Background

α2-adrenoceptors are important regulators of vascular tone and blood pressure. Regulation of cell proliferation is a less well investigated consequence of α2-adrenoceptor activation. We have previously shown that α2B-adrenoceptor activation stimulates proliferation of vascular smooth muscle cells (VSMCs). This may be important for blood vessel development and plasticity and for the pathology and therapeutics of cardiovascular disorders. The underlying cellular mechanisms have remained mostly unknown. This study explored pathways of regulation of gene expression and intracellular signaling related to α2B-adrenoceptor-evoked VSMC proliferation.

Results

The cellular mechanisms and signaling pathways of α2B-adrenoceptor-evoked proliferation of VSMCs are complex and include redundancy. Functional enrichment analysis and pathway analysis identified differentially expressed genes associated with α2B-adrenoceptor-regulated VSMC proliferation. They included the upregulated genes Egr1, F3, Ptgs2 and Serpine1 and the downregulated genes Cx3cl1, Cav1, Rhoa, Nppb and Prrx1. The most highly upregulated gene, Lypd8, represents a novel finding in the VSMC context. Inhibitor library screening and kinase activity profiling were applied to identify kinases in the involved signaling pathways. Putative upstream kinases identified by two different screens included PKC, Raf-1, Src, the MAP kinases p38 and JNK and the receptor tyrosine kinases EGFR and HGF/HGFR. As a novel finding, the Src family kinase Lyn was also identified as a putative upstream kinase.

Conclusions

α2B-adrenoceptors may mediate their pro-proliferative effects in VSMCs by promoting the activity of bFGF and PDGF and the growth factor receptors EGFR, HGFR and VEGFR-1/2. The Src family kinase Lyn was also identified as a putative upstream kinase. Lyn is known to be expressed in VSMCs and has been identified as an important regulator of GPCR trafficking and GPCR effects on cell proliferation. Identified Ser/Thr kinases included several PKC isoforms and the β-adrenoceptor kinases 1 and 2. Cross-talk between the signaling mechanisms involved in α2B-adrenoceptor-evoked VSMC proliferation thus appears to involve PKC activation, subsequent changes in gene expression, transactivation of EGFR, and modulation of kinase activities and growth factor-mediated signaling. While many of the identified individual signals were relatively small in terms of effect size, many of them were validated by combining pathway analysis and our integrated screening approach.

Keywords

Alpha2-adrenoceptorA7r5 cell lineVascular smooth muscle cellDNA microarrayKinase inhibitorKinase activity profilingFunctional analysisPathway analysis

Background

The α2-adrenoceptors, a subclass of the family of G-protein coupled receptors (GPCRs), are targets for cardiovascular drug development because they mediate important actions of noradrenaline and adrenaline in the regulation of vascular tone and blood pressure. The vascular effects of α2-adrenoceptor agonists are complex, as they reflect the results of the interplay between centrally mediated sympatholytic effects and pre- and postsynaptic α2-adrenoceptor activation in peripheral tissues [1]. The roles of the different α2-adrenoceptor subtypes in short-term cardiovascular regulation are relatively well known [26]. Indeed, central α2A-adrenoceptors are currently employed as targets of clonidine-like antihypertensive drugs [7], but vascular α2-adrenoceptors have so far not been exploited as cardiovascular drug targets.

Regulation of cell proliferation is a less well investigated consequence of α2-adrenoceptor activation. It has been reported to enhance the proliferation of many different breast cancer cell lines [811], primary rat proximal tubule cells [12], opossum kidney cells [13] and Chinese hamster lung fibroblasts [14]. Also inhibition of cholangiocarcinoma and pheochromocytoma cell proliferation by α2-adrenoceptor agonists has been reported [15, 16]. In many of these studies, the investigated cells expressed all three α2-adrenoceptor subtypes, making it impossible to specify the subtype(s) involved. Some of the studies indicated that enhanced proliferation was caused by activation of α2A-adrenoceptors [14] or α2B-adrenoceptors [11, 12], whereas inhibition of proliferation was ascribed to α2C-adrenoceptors [16]. However, little is known about the effects of α2-adrenoceptor activation on the proliferation of vascular smooth muscle cells (VSMCs). Our own previous results indicated that activation of α2B-adrenoceptors would have prominent stimulatory effects on the proliferation of cultured A7r5 rat VSMCs [17].

VSMC proliferation and differentiation are essential physiological processes in vascular development and plasticity. Phenotypic switching from differentiated to proliferative VSMCs includes reduced expression of contractile proteins, and increased expression of inflammatory cytokines, proteases and extracellular matrix proteins, and is involved in the development of many major cardiovascular diseases, such as atherosclerosis and hypertension. Increased VSMC proliferation also contributes to restenosis after coronary bypass or angioplasty, limiting the long-term success of these clinical interventions. Improved understanding of the mechanisms regulating VSMC proliferation may therefore guide the development of new therapies [1820]. In healthy vessels, VSMCs have very low rates of proliferation, but cell proliferation is stimulated by injury or insults to the vessel wall. Pathological loss of quiescence is triggered by release of mitogens from platelets and VSMCs. They activate signaling pathways that stimulate expression of cell-cycle genes. Inactivation of signals that normally repress VSMC proliferation is also required [19, 21, 22].

We have previously demonstrated that activation of α2B-adrenoceptors with the selective agonist dexmedetomidine potently increases the proliferation of cultured A7r5 cells, a commonly employed model of VSMCs [17]. However, the underlying cellular mechanisms and signal transduction pathways have remained unknown. We now employed three different screening assays to investigate changes in gene expression, signaling pathways and kinase activation profiles related to α2B-adrenoceptor-evoked VSMC proliferation. Another purpose of this study was to evaluate the suitability of DNA microarrays, kinase/phosphatase inhibitor library screening and kinase activity profiling assays for the investigation of these mechanisms.

Methods

Materials

A7r5 cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Fetal bovine serum was from PAA Laboratories GmbH (Pasching, Austria), trypsin-Versene® solution was from Lonza (Basel, Switzerland). M-PER Mammalian Extraction Buffer, Pierce™ BCA protein assay kit and Halt™ phosphatase and protease inhibitors were from Thermo Fisher Scientific (Waltham, MA, USA). Dulbecco’s modified Eagle’s medium (DMEM), Geneticin (G418 disulphate salt solution), trypsin, EDTA and DMSO were from Sigma Aldrich (St. Louis, MO, USA). Dexmedetomidine was a kind gift from Orion Pharma (Turku, Finland). Oligonucleotide primers were from Oligomer (Helsinki, Finland). Other chemicals and reagents were obtained from commercial suppliers.

Cell culture

A7r5-α2B cells transfected to stably express the human α2B-adrenoceptor were cultured and maintained as described previously [17]. Briefly, the cells were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 400 μg/ml Geneticin. Cells were grown to approximately 90% confluence in 75 cm2culture flasks. Cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2. The medium was changed every 3 days and the cells were passaged approximately once a week by dissociation with a solution of 0.025% trypsin and 0.1% EDTA.

RNA isolation

Twenty-four hours after treatment of A7r5-α2B cells with 100 nM dexmedetomidine or vehicle, total RNA was isolated using the NucleoSpin® RNA II mini spin kit (Macherey-Nagel, Düren, Germany) (n = 3). RNA concentration and purity were confirmed using optical density (OD) measurements at 260 nm and 280 nm (OD260/OD280 ratio of approximately 2.0).

DNA microarray gene expression analysis

Microarray experiments were used to determine gene expression profiles in A7r5-α2B cells after treatment with dexmedetomidine or vehicle. Microarray studies were performed at the Finnish DNA Microarray Centre at Turku Centre for Biotechnology. Two hundred nanogram of total RNA from each sample was amplified with Ambion’s Illumina™ RNA TotalPrep Amplification kit (Thermo Fisher Scientific). During the overnight in vitro transcription reaction, cRNA was labeled by biotinylation. Both before and after the amplifications, the RNA/cRNA concentrations were checked with Nanodrop ND-1000 (Thermo Fisher Scientific) and cRNA quality was controlled with the use of BioRad’s (Hercules, CA, USA) Electrophoresis station.

Labelled and amplified material (0.75 μg/array) was hybridized overnight to Illumina’s Sentrix® RatRef-12 BeadChips™ (Illumina Inc., San Diego, CA, USA) at 58 °C according to Illumina® Whole Genome Gene Expression with IntelliHyb Seal protocol (Revision B). Hybridization was detected with 1 μg/ml cyanine3-streptavidine (GE Healthcare Biosciences, Buckinghamshire, UK). The chips were scanned with an Illumina BeadArray™ reader. Numerical results were extracted using Illumina’s BeadStudio™ software without any normalization or background subtraction. The hybridization control report indicated that all hybridizations were successful.

The microarray data were analyzed using R statistical analysis software [23, 24] and the Limma package of the related Bioconductor module [25, 26]. After quality inspection, one outlier sample with considerably lower signal values from the A7r5-α2B control group (vehicle treatment) was discarded. The data were normalized using the quantile normalization method. After statistical testing with Limma, the differentially expressed genes were filtered requiring false discovery rates <0.05 and absolute fold-changes >1.3. This relatively low cut-off in effect size is justified by the exploratory nature of the study and the risk of false negative findings associated with a higher cut-off. Any false positive findings were seen not to cause serious risks for the subsequent pathway analysis and interpretation, as false positives most likely would represent random findings and not results in any systematic bias. The GeneFuncster tool was used to carry out enrichment analysis of all differentially expressed genes towards both Gene Ontology (GO) categories and KEGG pathways [27, 28]. Functional associations of the differentially expressed genes were further analyzed using Ingenuity Pathway Analysis (IPA) software (Ingenuity®Systems [29]).

Quantitative RT-PCR

To validate the microarray results, 1 μg of the RNA was transcribed to cDNA using the DyNAmo™ cDNA synthesis kit (Thermo Finnzymes, Vantaa, Finland), including controls with no reverse transcriptase enzyme. Quantitative RT-PCR was performed using the SYBR green kit (Kapa Biosystems, Wilmington, MA, USA). Primers specific for the selected genes (Table 1) were designed by using Universal Probe Library Assay Design Center (Roche, Basel, Switzerland). The final concentration of forward and reverse primers in the reaction was 0.2 μM. All measurements were made in triplicate for each sample (n = 3). The data were analyzed according to the 2−ΔΔCt method using GAPDH as a reference gene (relative expression to GAPDH) [30].
Table 1

Oligonucleotide sequences for quantitative RT-PCR analysis

Gene symbol

Left primer

Right primer

Glrx

GGC TCA GGA GTT TGT GAA CTG CAA G

ATC TGC TTC AGC CGG GCC GT

Cx3cl1

CCA CAA GAT GAC CTC GCC AAT C

TCC ACT GTG GCT GAC TCA GGC T

Cav1

AAC GAC GAC GTG GTC AAG A

CAC AGT GAA GGT GGT GAA GC

Prrx1

CTT CTC CGT CAG TCA CCT GC

CGT GCA AGA TCT TCC CGT AC

GAPDH

CAA CTC CCT CAA GAT TGT CAG CAA

GGC ATG GAC TGT GGT CAT GA

Glrx Glutaredoxin, Cx3cl1 Chemokine (C-X3-C motif) ligand / fractalkine, Cav1 Caveolin 1, Prrx1 Paired related homeobox 1, GAPDH Glyceraldehyde-3-phosphate dehydrogenase

Kinase and phosphatase inhibitor screening

Compounds

A compound library (former CAT# 2831A) from BioMol (Hamburg, Germany) with 84 known kinase and phosphatase inhibitors (annotations in Additional file 1) was screened. The compounds (and DMSO as control) were plated in 384-well plates at four different concentrations using an automated liquid handling station (Hamilton, Bonaduz, Switzerland). The final concentration range of the compounds was 0.0143 μM, 0.143 μM, 1.43 μM and 14.3 μM. The library screen was performed four times as separate biological replicates.

Inhibitor assay

The DELFIA® Cell Proliferation kit (PerkinElmer, Boston, MA, USA), based on the measurement of incorporation of the nucleoside analogue 5-bromo-2′-deoxyuridine (BrdU) during DNA synthesis in proliferating cells, was used to determine the effects of kinase and phosphatase inhibitors on the dexmedetomidine-evoked proliferation response of A7r5-α2B cells. Briefly, A7r5-α2B cells were serum-deprived o/n in DMEM supplemented with 0.5% FBS and seeded into 384-well plates (2.2-2.6 × 104 cells/well) on top of pre-plated inhibitors using a Multidrop™ Combi Reagent Dispenser (Thermo Fischer Scientific, Rockford, IL, USA). Cells were allowed to attach for 2 h at 37 °C before the addition of 100 nM (final concentration) dexmedetomidine or vehicle (DMEM supplemented with 0.5% FBS), each treatment on individual plates. Plates were incubated for 24 h and BrdU (10 μM) was added during the last 4 h. The cells were then fixed and labelled with an anti-BrdU-Eu antibody (0.5 μg/ml) for 75 min at RT under gentle agitation. Cells were washed five times (total 25 min), DELFIA Inducer solution was added and the plates were shaken vigorously for 30 min on a DELFIA plate shaker (PerkinElmer). An EnSight Multimode plate reader (PerkinElmer) was used for signal quantification.

Treatments (dexmedetomidine or vehicle) were performed on separate sample plates and proliferation responses were determined by comparing the inhibitor-treated samples to the DMSO-treated samples (baseline) on each sample plate separately. Total inhibitor effects were determined as an average of four inhibitor concentrations and statistical significance was determined based on these average values.

Statistical analysis

For each inhibitor, two-way analysis of variance (ANOVA) was employed to evaluate how concentration and treatment were associated with the proliferation response. All statistical tests were performed as 2-sided, with a significance level set at 0.05. The analyses were performed using SAS System, version 9.3 for Windows (SAS Institute Inc., Cary, NC, USA).

PamChip® kinase activity profiling

Preparation of protein samples for kinase activity profiling

A7r5-α2B cells were plated in 60 mm dishes and grown to approximately 90% confluence followed by serum deprivation o/n in DMEM supplemented with 0.5% FBS. Two series of dishes were treated in parallel with 100 nM dexmedetomidine (or vehicle) by replacing the entire medium for 5 min, 30 min, 2 h or 24 h. For each time point, 2 samples were treated with dexmedetomidine and 2 samples served as controls. After exposure for the desired time, the dexmedetomidine (or vehicle) solution was aspirated from the first series of samples, then the dishes were placed on ice and the cells were washed twice with ice-cold PBS. Cells were lysed with ice-cold M-PER Mammalian Extraction Buffer (Thermo Fischer Scientific) containing Halt™ phosphatase (1/100) and protease inhibitors (1/100) (both from Thermo Fischer Scientific). Lysates were incubated for 15 min in a shaking ice bath. Cell lysis was confirmed visually and completed by scraping. The lysates from the first series were transferred to the replicate dishes so as to lyse the contents of both dishes in the same buffer. Cell lysates were centrifuged for 15 min at 16.000 x g at 4 °C and supernatants were collected into clean vials, snap-frozen with liquid nitrogen and stored at −70 °C. Protein concentrations were determined with a protein assay kit (Pierce™ BCA protein assay kit, Thermo Fischer Scientific).

Protein kinase activity profiling

Kinase activity profiles were determined using the PamChip® 12 serine/threonine (STK) and protein tyrosine (PTK) peptide microarray system (PamGene International B.V., ‘s-Hertogenbosch, The Netherlands) [3134].

To prevent non-specific binding, the arrays on the PamChip® 12 STK chips were incubated with 2% bovine serum albumin (BSA) in water for 30 cycles (15 min). Arrays were then washed three times with kinase assay buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 0.01% Brij35). Reaction mixtures contained 0.01% BSA in kinase assay buffer supplemented with anti-phospho-Ser/Thr antibodies (PamGene International BV [31],) in a final volume of 40 μl per array. For each STK assay, 0.5 μg of sample protein was present in the reaction mixture. The reaction was initiated by the addition of ATP (final concentration 400 μM). Samples were pumped up and down through the porous membrane of the arrays for 60 cycles (in total 60 min). Arrays were washed and then incubated with a secondary antibody (polyclonal swine anti-rabbit Immunoglobulin/FITC) for 30 min. Images (10, 50 and 200 msec exposure time) were captured every 5 min with an integrated CCD-based optical system combined with Evolve software (version 1.5, PamGene International BV). The secondary antibody was removed and arrays were washed before post-wash images were taken at different exposure times (20, 50, 100 and 200 msec).

The PTK assay mixture contained kinase assay buffer, 0.01% BSA and 400 μM ATP, supplemented with 4 μl protein kinase-additive (PamGene International BV), 10 mM DTT and FITC-labeled anti-phosphotyrosine antibody (PamGene International BV). For each PTK assay, 5 μg of sample protein was used. Since a labeled antibody is present in the PTK assay mixture, peptide phosphorylation was monitored during incubation with assay mixture by capturing images every 5 min (10, 20, 50 and 200 msec exposure time), allowing real time recording of the reaction kinetics (one-step reaction). Arrays were washed and fluorescence was detected at different exposure times (20, 50, 100 and 200 msec).

Signal quantification

Fluorescence signal intensities for all peptides were analyzed using BioNavigator 6.1 software (PamGene International BV [35]), a statistical analysis and visualization software tool. Around each spot a local background was calculated, and then this value was subtracted from the signal intensity, resulting in SigmBg. For signal quantification, the slope of the SigmBg versus exposure times was calculated to increase the dynamic range. Visual quality control was done to exclude defective arrays from the analysis. Peptides with CV < 30% for the replicates were included in the analysis, resulting in 96 peptides for PTK and 98 peptides for STK analysis.

Statistical analysis

Significant effects (p < 0.05) were identified by fitting a model for the conditions which performs a Dunnet’s test for multiple conditions against a single control.

Pathway analysis and upstream kinase analysis

Peptides found to be significantly differently phosphorylated between dexmedetomidine-treated samples and their vehicle-treated controls (t = 30 min and t = 24 h) were used for pathway analysis with the canonical pathway analysis program MetaCore™ (Thomson Reuters, St. Joseph, MI, USA). The top 10 most significant process networks were identified and relevant signaling networks were assembled based on manually curated objects generated by log fold-change data. Pathways were ranked by -log (p), and -log (p) > 4 were considered significant. BioNavigator software was used to perform upstream PTK and STK analysis by comparing differentially phosphorylated peptides between dexmedetomidine-treated samples and their vehicle-treated controls (t = 30 min and t = 24 h) and linking (derived from the Kinexus phosphoNET database [36]) them to the putative upstream kinases responsible for their phosphorylation. The upstream kinase analysis tool generated hypotheses about kinases that were differentially active between dexmedetomidine-treated samples and their vehicle-treated controls.

Results

Illumina DNA microarray

The objective of this set of experiments was to identify specific genes involved in α2B-adrenoceptor-evoked VSMC proliferation. To define the effects of activated α2B-adrenoceptors on gene expression profiles, A7r5-α2B VSMCs were incubated with 100 nM dexmedetomidine for 24 h. Of the 22,000 genes (22,523 transcripts) analyzed, 55 genes (see Additional file 2) were differentially expressed in dexmedetomidine-treated cells compared with vehicle-treated controls (FC > 1.3 and p < 0.05; p-values corrected for false positive discovery rates). Out of these genes, 29 were upregulated with fold change (FC) values ranging from 1.32 to 2.01 and 26 were downregulated with FC values ranging from −1.3 to −1.86 (Fig. 1). Most of the genes identified have not been reported previously to be differentially expressed after dexmedetomidine treatment. To evaluate the functional associations of the observed gene expression profiles, the most significantly enriched biological processes, cellular components and functions among differentially expressed genes were identified.
Fig. 1

Fold change (FC) values of upregulated (red) and downregulated (green) genes in dexmedetomidine-treated (100 nM) A7r5-α2B vascular smooth muscle cells compared with vehicle-treated control cells in the Illumina DNA microarray. The genes are ordered based on the associated adjusted p-values, in decreasing order. Explanation of gene symbols, actual and adjusted p-values can be found in Additional file 2

GeneFuncster functional enrichment analysis

We analyzed the up- and downregulated gene lists by using the GeneFuncster tool, which can analyze the functional enrichment in short filtered gene lists towards both GO and KEGG and provide comprehensive result visualization for both databases (p-value limit for terms with detailed results: 0.01) [27]. In general, a high number (> 200) of significantly (p < 0.01) enriched biological processes was found among the differentially expressed genes induced by α2B-adrenoceptor activation. Analysis of cellular component GO terms and molecular function GO terms resulted in 29 and 10 significant enrichments, respectively (Additional file 3). Of the first 200 enriched biological process GO terms, 49 were related to cardiovascular system development, blood circulation, cell migration and motility, cell proliferation, cell adhesion, vasoconstriction, mitotic cell cycle, cytoskeleton organization and regulation of cell shape (Fig. 2). Notably, GO terms such as “regulation of smooth muscle cell proliferation” (GO: 0042127), “positive regulation of cell proliferation” (GO: 0048660) and “positive regulation of vasculature development” (GO: 1,904,018) were among the enriched biological process GO terms.
Fig. 2

Selected significantly enriched (p < 0.01) biological process GO terms related to cardiovascular functions in upregulated (red) and downregulated (green) genes induced by α2B-adrenoceptor activation upon dexmedetomidine stimulation in A7r5-α2B vascular smooth muscle cells. Explanation of gene symbols in Additional file 2

Some of the differentially expressed genes were involved in several aspects of cell function, including cardiovascular system development, regulation of proliferation, migration and adhesion, vasoconstriction and mitotic cell cycle. Upregulated genes which had the largest number of annotations within the selected 49 biological process GO terms were prostaglandin-endoperoxide synthase 2 (Ptgs2 or COX2; 38 annotations), early growth response 1 (Egr1; 29 annotations), serpin peptidase inhibitor (Serpine1 or plasminogen activator inhibitor type 1; PAI-1; 28 annotations), coagulation factor III, tissue factor (F3; 24 annotations), and podoplanin (Pdpn; 21 annotations). Downregulated genes with the most annotations per gene were chemokine (C-X3-C motif) ligand 1 (Cx3cl1 or fractalkine; 40 annotations), Rhoa (34 annotations), Cav1 (33 annotations), chemokine (C-C motif) ligand 2 (ccl2; 29 annotations), Icam1 (28 annotations) and tropomyosin 1 alpha (Tpm1; 23 annotations). Among the differentially expressed genes were many genes that are known to participate in the regulation of proliferation in different types of cells, such as Egr1, Serpine1, Pdpn, Cx3cl1, glutaredoxin (Glrx), cell division cycle 20 (cdc20), kinesin family member 20a (Kif20a) and ubiquitin-conjugating enzyme E2C (ube2c). However, in A7r5 VSMCs, very little is known about the function of most of these genes.

Ingenuity® pathway analysis

The results of the Illumina DNA microarray were imported into the Ingenuity® pathway analysis (IPA) application and a functional pathway analysis was performed to identify significant biological functions, networks and upstream regulators related to the differentially expressed genes in dexmedetomidine-stimulated vs. vehicle-treated A7r5-α2B cells. The top 10 up- and down-regulated genes identified by IPA Core Functional Analysis are listed in Table 2 and include partly the same genes that were determined to be involved in many of the functionally enriched biological process GO terms in the GeneFuncster functional enrichment analysis: Egr1, Glrx, Kif20a, Cx3cl1, Rhoa, Cav1 and Ccl2.
Table 2

Differentially expressed genes following α2B-adrenoceptor activation compared with vehicle-treated control according to IPA

Gene symbol

Gene name

Fold change

P-value

Up-regulated genes

 Lypd8

LY6/PLAUR domain containing 8

2.01

4.2·10−6

 Glrx

glutaredoxin

1.60

1.0·10−3

 LOC500300

similar to hypothetical protein MGC6835 (Depp)

1.58

4.0·10−3

 Procr

protein C receptor

1.56

5.7·10−3

 Egr1

early growth response 1

1.54

5.0·10−3

 Rpl37

ribosomal protein L37

1.51

1.0·10−3

 Kif20a

kinesin family member 20a

1.47

1.3·10−2

 Oasl

2′-5′-oligoadenylate synthetase-like

1.46

5.0·10−3

 Fam25a

family with sequence similarity 25, member A

1.45

4.0·10−3

 Ppial4g

peptidylprolyl isomerase A like 4G

1.45

2.3·10−2

Down-regulated genes

 Cx3cl1

chemokine (C-X3-C motif) ligand 1

−1.86

1.7·10−5

 Ccl2

chemokine (C-C motif) ligand 2

−1.74

4.4·10−4

 Ahnak

AHNAK nucleoprotein

−1.47

2.3·10−2

 Npm3

nucleophosmin/nucleoplasmin 3

−1.45

3.0·10−2

 Nid1

nidogen 1

−1.44

8.7·10−3

 Tnnt2

troponin T2, cardiac type

−1.42

6.0·10−3

 Zfp36l2

zinc finger protein 36, C3H type-like 2

−1.40

4.4·10−2

 Ccl7

chemokine (C-C motif) ligand 7

−1.40

2.0·10−2

 Cav1

caveolin 1

−1.39

8.2·10−3

 Rhoa

ras homolog family member A

−1.38

2.4·10−2

The most significant biological functions predicted by the IPA core analysis included (changes in) cellular movement, cell-to-cell signaling, cellular growth and proliferation, cellular development, skeletal and muscular system development and function and cell cycle, with a total of 42 putative genes (Table 3A). Moreover, these categories contained the following functions specifically related to smooth muscle cells (SMCs): migration (5 genes), adhesion (2 genes), proliferation (9 genes) and contraction (3 genes). A further gene set with 15 altered gene targets was involved in cell cycle regulation. P-values in the range of 1.34 × 10−10 to 2.49 × 10−3 indicated statistical significance. Table 3B summarizes the differentially expressed genes involved in SMC-specific functions and includes the upregulated genes Egr1, Ptgs2, Serpine1 and F3 and the downregulated genes Rhoa, Cx3cl1, Cav1, natriuretic peptide b (Nppb or BNP) and paired related homeobox 1 (Prrx1). Egr1, Ptgs2, Serpine1 and F3 were involved in migration and proliferation of SMCs. Ptgs2 was also involved in SMC contraction. Downregulation of Rhoa was associated with migration, adhesion, proliferation and contraction of SMCs. Downregulation of Cx3cl1 was associated with adhesion and proliferation. Downregulation of Cav1 was associated with VSMC proliferation and contraction. Other downregulated genes associated with cell proliferation were Nppb and Prrx1. The full list of significant biological functions and diseases identified by IPA can be found in Additional file 4.
Table 3

Significant biological functions predicted by IPA (A) and differentially expressed genes involved in SMC-specific functions (B)

A. Significant biological functions (42 genes in total)

Category

P-value

Number of involved genes

Cellular movement

1.34∙10−10 − 2.31∙10−3

25

 Migration of SMCs

9.87∙10−5

5

 Migration of VSMCs

2.35∙10−4

4

Cell−to−cell signaling and interaction

1.34∙10−10 − 2.45∙10−3

19

 Adhesion of SMCs

7.95∙10−4

2

Cellular growth and proliferation

4.21∙10−7 − 2.49∙10−3

27

 Proliferation of SMCs

4.21∙10−7

9

Skeletal and muscular system development and function

4.21∙10−7 − 2.24∙10−3

18

 Contraction of SMCs

2.17∙10−3

3

Cell cycle

5.27∙10−7 − 1.50∙10−3

15

B. Differentially expressed genes involved in SMC−specific functions

Category

Involved genes

Migration of SMCs

↑ Egr1, ↑ Ptgs2, ↑ Serpine1, ↑ F3, ↓ Rhoa

Migration of VSMCs

↑ Egr1, ↑ Ptgs2, ↑ Serpine1, ↓ Rhoa

Adhesion of SMCs

↓ Cx3cl1, ↓ Rhoa

Proliferation of SMCs

↑ Egr1, ↑ Ptgs2, ↑ Serpine1, ↑ F3,

↓ Nppb, ↓ Cx3cl1, ↓ Rhoa, ↓ Prrx1, ↓ Cav1

Contraction of SMCs

↑ Ptgs2, ↓ Rhoa, ↓ Cav1

↑ = upregulated, ↓ = downregulated, Egr1 = early growth response 1, Ptgs2 = prostaglandin−endoperoxide synthase 2 (COX−2), Serpine1 = serpin family E member 1 (plasminogen activator inhibitor−1 = PAI−1), F3 = coagulation factor III, tissue factor, Rhoa = ras homolog family member A, Cx3cl1 = chemokine (C−X3−C motif) ligand 1, Nppb = natriuretic peptide B, Prrx1 = paired related homeobox 1, Cav1 = caveolin 1

Comparison of genes identified with GeneFuncster and IPA

We have shown in our earlier study that proliferation of A7r5-α2B VSMCs is significantly increased when the cells are stimulated with the α2-adrenoceptor agonist dexmedetomidine [17]. In the current study, the expression of a number of genes involved in VSMC proliferation was changed as a consequence of α2B-adrenoceptor activation in dexmedetomidine-treated A7r5-α2B cells as identified by IPA core analysis (Fig. 3a) and GeneFuncster functional enrichment analysis (Fig. 3b and c). According to the IPA core analysis, upregulation of Egr1 (FC 1.54; P = 0.005), F3 (FC 1.38; P = 0.008) and Ptgs2 (FC 1.45; P = 0.02) is predicted to lead to activation of SMC proliferation. Cav1 (FC -1.39; P = 0.008) and Nppb (FC -1.33; P = 0.02) are predicted to have inhibitory effects on SMC proliferation, which is in line with the observed decreased expression of these genes. According to IPA, Cx3cl1, Prrx1 and Rhoa have indirect activating effects on SMC proliferation. However, in our results, Cx3cl1 (FC -1.86; P = 0.00002), Prrx1 (FC -1.32; P = 0.04) and Rhoa (FC -1.38; P = 0.02) were downregulated, which is inconsistent with the predicted actions of these genes in the IPA core analysis. Serpine1 (FC 1.44; P = 0.008) is indicated to be involved in the proliferation of SMCs, but IPA does not predict the direction of the effect. GeneFuncster identified the biological process GO terms “regulation of smooth muscle cell proliferation” and “regulation of cell proliferation” as significantly enriched, with P-values of 2.1 × 10−5 and 1.2 × 10−4, respectively. The differentially expressed genes linked to these GO terms were mainly the same as the ones identified by IPA. Egr1, Ptgs2, Cx3cl1, Cav1 and Nppb were linked to both GO terms (Fig. 3b and c). In GeneFuncster, F3, Serpine1, Rhoa and Prrx1 were linked only to general regulation of cell proliferation, although IPA identified them as genes regulating SMC proliferation.
Fig. 3

Network of differentially expressed genes in dexmedetomidine-stimulated A7r5-α2B vascular smooth muscle cells involved in the regulation of smooth muscle cell proliferation according to Ingenuity Pathway Analysis (a) and differentially expressed genes annotated in the biological process GO terms “regulation of smooth muscle cell proliferation” (GO:0042127) (b) and “positive regulation of cell proliferation” (GO:0048660) (c) according to GeneFuncster functional enrichment analysis. Red and green colors indicate upregulation and downregulation, respectively. Explanation of gene symbols in Additional file 2

IPA upstream regulator analysis

We also conducted upstream regulator analysis using IPA. This analysis determines likely upstream regulators that are connected to dataset genes through a set of direct or indirect relationships and predicts their activation state. For a particular regulator, the overlap P-value measures enrichment of genes regulated by this regulator in the dataset without taking into account the regulation direction. The activation z-score is used to predict activation or inhibition of regulators based on relationships with dataset genes and direction of change of dataset genes and a prediction of effect on the function, increased or decreased, is given for |z-score| >2. For our dataset, upstream regulator analysis identified six upstream regulators with |z-score| >2: platelet activating factor (PAF), hepatocyte growth factor (HGF), basic fibroblast growth factor (bFGF/FGF2), cyclic AMP (cAMP) and aryl hydrocarbon receptor (AHR) were predicted to be activated and NF-kappa-B inhibitor alpha (NFKBIA) was predicted to be inhibited. The predicted effects of these upstream regulators on differentially expressed genes in our dataset are illustrated in Fig. 4a. There were 9 genes (proteins) in the dataset showing regulatory effects by NFKBIA. Among them, 8 genes had expression change directions consistent with the inhibition of NFKBIA (z-score = −2.482, overlap P-value = 1.9 × 10−7). Seven of nine genes and 10 of 11 genes showed expression change directions consistent with the activation of FGF2 (z-score = 2.140, overlap P-value = 3.6∙10−5) and HGF (z-score = 2.203, overlap P-value = 4.9∙10−7), respectively. Five genes indicated regulatory effects by cAMP (z-score = 2.141, overlap P-value = 5.1∙10−4), six genes by PAF (z-score = 2.159, overlap P-value = 1.4∙10−7) and seven genes by AHR (z-score = 2.183, overlap P-value = 1.5∙10−3), and all genes had expression change directions consistent with the activation of these upstream regulators.
Fig. 4

Upstream regulators identified by Ingenuity Pathway Analysis, predicted to participate in the regulation of gene expression upon α2B-adrenoceptor activation in A7r5-α2B vascular smooth muscle cells. The network of upstream regulators with │z-score│ > 2 is illustrated in panel (a). The network of PKC, PKA and Pdgf targets is presented in panel (b). Red and green colors indicate upregulation and downregulation, respectively. Explanation of gene symbols in Additional file 2

Protein kinase C (different isoforms, PKCs), protein kinase A (PKA) and platelet derived growth factor (PDGF) obtained z-scores of 1.788, 1.980 and 1.988, respectively. Because they did not reach a z-score of 2, IPA did not give a prediction on their activation state. However, based on their relatively high z-scores, activation may be assumed. PKC, PKA and PDGF are known to regulate the proliferation of many cell types, including VSMCs; therefore, we inspected their roles as upstream regulators of the genes in our dataset (Fig. 4b). Six genes demonstrated regulatory effects by PKCs and among them, five genes had expression change directions consistent with the assumed activation of PKCs (overlap P-value = 1.7∙10−5). Six of seven genes and four of four genes showed changes consistent with the assumed activation of Pdgf (overlap P-value = 6.0∙10−9) and PKA (overlap P-value = 3.9∙10−4), respectively.

Validation by RT-PCR

To validate the microarray results, we analyzed the expression of selected genes by means of quantitative RT-PCR, using the same samples as in the microarray experiment. These genes were chosen to represent a spectrum of significant expression level changes in the microarray. Out of the differentially expressed genes that were annotated within the selected 49 biological process GO terms, Glrx was the most upregulated gene (FC 1.60) and Cx3cl1 was the most downregulated gene (FC −1.86). Cav1 (FC −1.39) and Prrx1 (FC −1.32) represent genes with smaller expression level changes. All selected genes were associated with significantly enriched biological process GO terms or the network of differentially expressed genes involved in the regulation of SMC proliferation shown in Figs. 2 and 3, respectively. Consistent with the microarray results, the expression differences (FC) for Glrx and Cx3cl1 were 1.75 and −3.02, respectively. Cav1 and Prrx1 represented genes with smaller FC-values in the microarray; they did not show differential expression compared to control samples in the RT-PCR experiments (Table 4).
Table 4

RT-PCR verification of selected differentially expressed genes in the dexmedetomidine-treated vs. vehicle-treated control samples

Gene symbol

Gene name

Microarray p-value

Microarray FC

RT-PCR FC

Glrx

glutaredoxin 1

0.0010

1.60

1.75

Cx3cl1

chemokine (C-X3-C motif) ligand 1

0.000017

−1.86

−3.02

Cav1

caveolin 1

0.0082

−1.39

−1.05

Prrx1

paired related homeobox 1

0.045

−1.32

−1.01

Screening of a kinase/phosphatase inhibitor library

The objective of this set of experiments was to investigate the effects of different kinase and phosphatase inhibitors on the α2B-adrenoceptor-evoked proliferation in A7r5-α2B VSMCs and possibly identify specific signaling pathways involved in the proliferation response. We screened an 84-compound library consisting of 70 kinase inhibitors and 14 phosphatase inhibitors for their effects on cell proliferation.

The inhibitor responses showed rather large variation between the biological replicates, and statistical analysis was employed to evaluate the significance of the inhibitor effects. We detected altogether 15 compounds that inhibited the dexmedetomidine-induced proliferation response in A7r5-α2B cells with statistical significance (p < 0.01). Another 18 inhibitors were associated with trend-level effects with 0.01 < p < 0.05. Statistical significance of inhibitor effects was determined by comparing averaged inhibitor effects (average of four concentrations) on the proliferation response in dexmedetomidine- and vehicle-treated cells. Statistically significant (p < 0.01) inhibitors repressed the dexmedetomidine-induced proliferation response by 16 to 32% when compared to vehicle-treated control cells (Fig. 5). Their potential target kinases and phosphatases are listed in Table 5, and include receptor (EGFR) and cytosolic (Src, BTK) tyrosine kinases, serine/threonine kinases (p38 MAPK, CK2, JNK, Cdks, Raf-1) as well as phosphatases (calcineurin, protein tyrosine phosphatases) known for their important functions in cell signaling and regulation of cell proliferation, differentiation, migration and apoptosis. More information on the pathways possibly involved in the observed effects is given in Additional file 5.
Fig. 5

Effects of statistically significant (p < 0.01) inhibitors on the proliferation of dexmedetomidine-stimulated A7r5-α2B vascular smooth muscle cells, in relation to vehicle-treated control cells. Treatments (dexmedetomidine or vehicle) were performed on separate sample plates and proliferation responses were determined by comparing the inhibitor-treated samples to the DMSO-treated samples (baseline) on each sample plate separately. Total inhibitor effects were determined as an average of four inhibitor concentrations and statistical significance was determined based on these average values. Error bars indicate standard deviation

Table 5

Significant (p < 0.01) inhibitors, their potential target kinases and phosphatases and their effects on VSMC proliferation

Inhibitor

Inhibition of proliferation

[% of control]

Potential target kinases and phosphatases

Effect of target kinase/phosphatase on VSMC proliferation

Reference

Fenvalerate

32

calcineurin

[61, 173175]

5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole

31

CK2

[176, 192, 303305]

Cdk9

[306, 307]

PP2

31

Src family kinases

[177182, 308]

PP1

18

SP600125

30

JNKs

[183, 184]

SB-202190

30

p38 MAPKs

[185187]

Olomoucine

29

Cdk1, Cdk2

[85, 188191]

Benzylphosphonic acid

27

tyrosine phosphatases

↑/↓

[309311]

L-p-bromotetramisole

25

alkaline phosphatase

n.d.

[312, 313]

tyrosine phosphatases

↑/↓

[309311]

LFM-A13

24

BTK, Plk, Jak2

[314317]

Daidzein

24

arrests cell cycle at G1

[318320]

LY294002

23

PI3-kinases

[173, 180, 192195]

Tyrphostin AG 1478

21

EGFR

[179, 196199]

2-Aminopurine

17

PKR

[321, 322]

GW5074

16

Raf-1

[37, 177, 200]

CK2 = protein kinase CK2 (casein kinase), Cdks 1,2 and 9 = cyclin-dependent kinases 1,2 and 9, Src family kinases = Src, Fyn, Hck and Lck, JNKs = c-Jun N-terminal kinases, p38 MAPKs = p38 mitogen-activated protein kinases, BTK = Bruton’s tyrosine kinase, Plk = Polo-like kinase, Jak2 = Janus kinase 2, PI3 kinase = phosphoinositide 3-kinase, EGFR = epidermal growth factor receptor, PKR = ds-RNA-activated protein kinase, Raf-1 = RAF proto-oncogene serine/threonine-protein kinase. In cases when little data are available in VSMCs, the table was augmented with information of kinase/phosphatase effects on cell proliferation in other cell types

Kinase activity profiling

PTK and STK activity profiles of dexmedetomidine-stimulated A7r5-α2B cells

The objective of this set of experiments was to investigate the activity profiles of protein tyrosine kinases (PTK) and serine/threonine kinases (STK) in A7r5-α2B cells after 5 min, 30 min, 2 h or 24 h stimulation with the agonist dexmedetomidine, and to further identify signaling proteins/pathways involved in the generation of the α2B-adrenoceptor-evoked proliferation response. We searched for new targets of α2B-adrenoceptor signaling using two different microarrays with 144 peptides on each chip, representing known phosphorylation sites of PTKs or STKs. PTK and STK profiling of dexmedetomidine- vs. vehicle-treated A7r5-α2B cells resulted in clear activity signals and high experimental quality. Out of the 144 peptides, 96 peptides on the PTK chip and 98 peptides on the STK chip were detected above threshold level in one or more of the samples.

Figure 6 shows statistically significant (p < 0.05) effects of dexmedetomidine exposure at different time points on the PTK (A) and STK (B) chips, being either significantly increased (green) or decreased (blue) compared with vehicle-treated control samples. Most remarkable differences in kinase activation profiles were observed after 30 min dexmedetomidine exposure, where altogether 40 peptides (PTK + STK) showed decreased phosphorylation when compared to vehicle-treated controls (Fig. 7). The generated tyrosine kinase and serine/threonine kinase activity profiles showed that dexmedetomidine stimulation induced transient decreases of kinase signaling at the early time points, 5 min and 30 min, which then recovered at the later time points resulting in slight activation of kinase signaling at 24 h. Changes in kinase activities were more substantial on the PTK chip: decreased phosphorylation of 9 peptides or 36 peptides was detected after 5 min or 30 min of dexmedetomidine exposure, respectively. On the STK chip, increased or decreased phosphorylation was detected in 2 (5 min) and 4 peptides (30 min), respectively (Fig. 7). After 24 h of dexmedetomidine exposure, slightly increased kinase activities could be detected; increased phosphorylation of 8 peptides on the PTK chip and 1 peptide on the STK chip was seen.
Fig. 6

Protein tyrosine kinase (PTK, panel a) and serine/threonine kinase (STK, panel b) activity profiles at 5 min, 30 min, 2 h and 24 h in A7r5-α2Bvascular smooth muscle cells treated with 100 nM dexmedetomidine (DEX) or vehicle (ctrl). Peptides on the chips represent known phosphorylation sites of PTKs and STKs; for clarity, the names of these kinases and their UniProt identifiers are used instead of the peptide sequences. Two artificial (ART025 and ART004) peptides are included in the figure; they are not derived from natural proteins, but they were selected from a library of peptides known to be targets of kinase phosphorylation. Green and blue colors indicate increased or decreased kinase activity, respectively, in dexmedetomidine-treated cells when compared with vehicle-treated controls. Black color indicates no differences between dexmedetomidine-treated cells and vehicle-treated controls. The replication CV of high signal spots on the PTK and STK chips was <20%, indicating good experimental quality. n = 3 per time point; except for t = 5 min in the PTK experiment, t = 30 min (ctrl) and t = 24 h (ctrl) in the STK experiment, where n = 2

Fig. 7

Number of peptides with significantly increased or decreased phosphorylation (p < 0.05) and expected proportion of false discoveries (FDR) on protein tyrosine kinase (PTK) and serine/threonine kinase (STK) chips at different time points. The FDR bar indicates the expected proportion (%) of false discoveries per time point on each chip

Canonical pathway analysis of kinase activity data significantly changed at 30 min and 24 h

At the 30 min time point, significant decreases of Raf-1, MEK1 and MEK2 phosphorylation were detected following dexmedetomidine-induced α2B-adrenoceptor activation. The Raf-1-MEK-ERK pathway is one of the best characterized MAP kinase signaling pathways, known to regulate cell proliferation [37]. Also phosphorylation of epidermal growth factor receptor (EGFR), known to provoke the activation of MAP kinases, was significantly decreased. In addition, decreased phosphorylation of linker for activated T cells (LAT), platelet derived growth factor receptor (PDGFR), erythropoietin receptor (Epo-receptor), spleen tyrosine kinase (Syk), phospholipase C γ (PLCγ), phosphoinositide-dependent kinase (PDK) and tyrosine protein kinase Fer were detected.

The kinase phosphorylation activities measured on peptides showing different responses on both PTK and STK chips were further evaluated by canonical pathway analysis (GeneGo MetaCore™) at 30 min, where kinase signaling was clearly decreased, and at 24 h, where kinase signaling was reversed to slight activation. Pathways with -log(p) > 4 were considered significant. At the 30 min time point, more than 10 pathways were identified as significant with –log(p) ranging from 7 to 10 (Additional file 6); dexmedetomidine-induced α2B-adrenoceptor activation inhibited all of these pathways. Based on their names, most of the significant pathways appeared less relevant from the point of view of α2B-adrenoceptor-evoked cell proliferation; nonetheless, also the following pathways containing pertinent signaling cascades were included in the top ten significant pathways: “Signal transduction_IP3 signaling”, “Development of EPO-induced PI3K/AKT pathway and Ca2+ influx” and “Development of EPO-induced MAPK pathway”. The Raf-1 - MEK1 - MEK2 signaling cascade appeared in most of these pathways, as well as interactions of PLCγ with LAT, PDGFR or Syk and interactions of the Epo-receptor with Syk and PLCγ. In addition, EGFR, PDK and Fer appeared in many of the significant pathways.

At the 24 h time point, increased phosphorylation by altogether 9 kinases was observed (Fig. 6), indicating delayed α2B-adrenoceptor-evoked increases in kinase activity. However, all pathways identified by the canonical pathway analysis at this time point (Additional file 6) had -log(p) < 4 and, thus, had low statistical significance. Receptor tyrosine kinases and cytosolic kinases showing increased phosphorylation activity in the identified pathways included Epo-receptor, lymphocyte-specific protein tyrosine kinase (Lck), cell division protein kinase 2 (Cdk2), Ser/Thr kinase Nek2 and vascular endothelial growth factor receptor 1 (VEGFR1). The phosphorylation of target peptides by Lck, Nek2 and VEGFR1 was clearly increased, whereas Cdk2 and Epo-receptor showed lesser extents of activation.

It is noteworthy to mention that for five kinases, the dexmedetomidine-induced activation of α2B-adrenoceptors first resulted in decreased phosphorylation at the 30 min time point with increased phosphorylation detected at 24 h. These kinases included Fyn-related kinase (Frk), tyrosine kinase Tec, platelet endothelial cell adhesion molecule (PECAM), Cdk2 and Epo-receptor (Fig. 6a).

Putative upstream kinase analysis

The canonical pathway analysis performed in GeneGo disregards different phosphorylation sites in the same protein. Therefore, an additional upstream kinase analysis was performed using a computational tool developed by PamGene that is able to link differentially phosphorylated peptides to the upstream kinases that might be responsible for their phosphorylation. Putative PTK and STK upstream kinases are presented in Additional file 7.

At 30 min, an overall decrease in kinase signaling due to dexmedetomidine-evoked α2B-adrenoceptor activation was detected. Most specific putative upstream tyrosine kinases included c-Src kinase (CSK), Src family kinase Fgr, hepatocyte growth factor receptor (HGFR; c-MET), EGFR, tyrosine kinase ABL2 (also known as Arg) and receptor tyrosine kinase ErbB-2. In addition to Fgr, all other eight members of the Src family kinases were among the putative upstream kinases (Lyn, Blk, Hck, Src, Fyn, Yes, Frk and Lck). Also many receptor tyrosine kinases were included: ErbB-3 and ErbB-4, fibroblast growth factor receptors 1-4 (FGFR1-4), vascular endothelial growth factor receptors 2 and 3 (VEGFR-2 = KDR; VEGFR-3 = Flt4) and tropomyosin receptor kinases A, B and C. In addition, tyrosine kinase ABL1 and all Tec family kinases (Tec, Btk, Itk, Bmx, Txk) appeared in the list of putative upstream tyrosine kinases. The most specific putative upstream serine/threonine kinases included atrial natriuretic peptide receptors A and B (ANPa, ANPb), serum/glucocorticoid regulated kinases (Sgk, Sgk2, Sgk3), G protein-coupled receptor kinase 1 (Grk1, RHOK), inhibitor of nuclear factor kappa-B kinases beta and epsilon and extracellular-signal-regulated kinase 5 (ERK5). Nine isozymes of the PKC family (α, β1, γ, δ, ι, η, θ, ξ) and five cyclin-dependent kinases (Cdk1, Cdk2, Cdk3, Cdk6, Cdk7) were among the putative upstream Ser/Thr kinases. In addition, many members of the MAPK signaling pathways, including Raf-1, MEK1/2, ERK1/2, p38 kinases and c-Jun N-terminal kinases (JNKs), appeared on the list of putative upstream Ser/Thr kinases.

After 24 h of dexmedetomidine stimulation, slight activation of kinase signaling was observed. At this later time point, putative upstream tyrosine kinases included many kinases that showed decreased activity at the earlier time points: ABL1 and ABL2, Tec family kinases Bmx and Ltk, receptor tyrosine kinases HGFR, EGFR and VEGFR-2 and several Src kinase family members (Frk, Hck, Yes, Src). Similar changes in kinase activity from decreased activity at earlier time points to increased activity at later time points was also observed for certain putative upstream Ser/Thr kinases, such as several PKC isozymes (α, β1, γ, δ, ι, η, θ, ξ), p38 kinases and JNK kinases. In addition to several PKC isoforms, the most specific putative upstream serine/threonine kinases included calcium/calmodulin-dependent protein kinase type IV (CAMK4), serine/threonine-protein kinase H1 (PSKH1), mitogen- and stress-activated protein kinase-1 (MSK1), cyclin-dependent kinase family member CRK7, cyclin-dependent kinase-like 1, 2 and 4 (Cdkl1, Cdkl2, Cdkl4) and the beta adrenergic receptor kinases 1 and 2 (BARK1/Grk2, BARK2/Grk3).

Discussion

Proliferation and migration of VSMCs are involved in the development of many major cardiovascular diseases, and improved understanding of the mechanisms that control these processes might allow the development of novel approaches to treat various vascular diseases, such as atherosclerosis and restenosis [38]. VSMCs regulate blood vessel diameter, blood pressure and blood flow distribution by their capacity to contract and relax in the vessel wall. Unlike many other cell types, VSMCs retain considerable plasticity even in adult organisms. Differentiated VSMCs express high levels of smooth muscle-specific contractile proteins, such as smooth muscle α-actin and myosin heavy chain. Upon inflammatory stimulation or injury, the cells may de-differentiate to a proliferative state - a phenomenon called phenotypic switching. The proliferative phenotype is characterized by downregulation of smooth muscle differentiation markers and increased production of e.g. extracellular matrix components, cytokines and chemokines [21, 22, 39, 40]. Indeed, VSMCs constantly integrate complex signals present in their local environment, mediated by mechanical forces, neuronal effects, extracellular matrix signals, cytokines and growth factors, and the combination of these signals determines the patterns of gene expression and cell phenotype [40].

α2-Adrenoceptor activation may both increase and inhibit cell proliferation, depending on the cell type, and we have previously reported that activation of α2B-adrenoceptors greatly enhances the proliferation of A7r5 VSMCs [17]. However, the underlying molecular mechanisms have remained unknown. The aim of this study was to shed light on the mechanisms involved in the α2B-adrenoceptor-evoked enhancement of proliferation in A7r5 VSMCs by exploiting DNA and kinase activity profiling microarrays and kinase/phosphatase inhibitor library screening. By combining such different types of screening assays, we aimed to sketch a general overview of the intracellular mechanisms involved in the generation of the α2B-adrenoceptor-evoked proliferation response of A7r5 VSMCs.

DNA microarray: Differentially expressed genes in the regulation of VSMC proliferation

We employed whole-genome microarray analysis and the selective α2-adrenoceptor agonist dexmedetomidine to identify differentially expressed genes that are involved in the α2B-adrenoceptor-evoked proliferation response of A7r5-α2B cells. Altogether 55 genes were differentially expressed upon α2B-adrenoceptor activation; approximately half of these were upregulated and half were downregulated. Although signaling and regulation of α2-adrenoceptors has been extensively investigated in other cell types [8, 4151] and to some extent also in VSMCs [17, 5258], less is known about how α2-adrenoceptor activation modulates gene expression in different types of cells, let alone VSMCs. Four differentially expressed genes from the microarray experiment were selected to be verified by means of quantitative RT-PCR. We were able to verify the altered expression levels of Glrx and Cx3cl1, representing the extremes of the FC spectrum in the microarray data, but genes with small microarray FC values did not show differential expression in the qRT-PCR experiments. It is well known that for microarray expression changes <1.4-fold, microarray and qPCR results do not always agree [59].

Only few reports exist on the effects of adrenoceptor activation on gene expression in VSMCs. Activation of α1- and β-adrenoceptors altered gene expression in A7r5 cells; 85% and 75% of the regulated genes displayed decreased expression, respectively. Both α1- and β-adrenoceptors inhibited the proliferation of A7r5 cells, but the microarray results indicated different mechanisms for inhibition of cell proliferation: α1-adrenoceptor activation induced expression of metabolic genes, whereas β-adrenoceptor activation changed the expression of genes encoding signaling and structural proteins [60]. In contrast, activation of α1-adrenoceptors increased the proliferation of primary rat aortic VSMCs [61]. These opposing effects may have been caused by different α1-adrenoceptor subtypes present in these systems, or different receptor signaling in the two VSMC models. In our study, activation of α2B-adrenoceptors led to increased DNA synthesis and proliferation of A7r5 cells, in association with up- or downregulation of distinct sets of genes. Thus, different members of the adrenoceptor family appear to regulate multiple aspects of biological functions in VSMCs, and their activation can induce opposing effects.

The up- and downregulated gene lists derived from our microarray data were further analyzed using the functional annotation tools GeneFuncster and Ingenuity® pathway analysis. The aim was to identify enriched biological processes, significant networks and upstream regulators related to the differentially expressed genes. The GeneFuncster (GF) analysis yielded more than 200 significantly enriched biological processes; 25% of these were related to cardiovascular system development, cell proliferation, migration, adhesion, cell cycle and vasoconstriction. Also the IPA core analysis detected similar functions specifically related to SMCs, including migration, adhesion, proliferation and contraction.

Both functional analyses identified essentially the same genes to be involved in these functions. Next, we contemplate the roles of individual genes in VSMC proliferation and related functions. For a majority of the regulated genes, the direction of change in expression and the observed effect on cell proliferation were in line with what has been published in the literature. These genes included Egr1, F3, Ptgs2, cdc20, Serpine1, Kif20a, ube2c, Diaph3, Cav1, Rhoa, Nppb and Tpm1. For some genes, however, the observed change in expression and the associated effect on proliferation differed from previously reported effects. These genes included Glrx, Cx3cl1, ccl2, ICAM-1 and Prrx1.

Interestingly, the most highly upregulated gene in our dataset, Ly6/PLAUR domain containing 8 (Lypd8; FC = 2.01, p = 4.2 × 10−6) did not receive any annotations in the functional analyses. Lypd8 is a member of the Ly6/PLAUR family of glycophosphatidylinositol-anchored cell surface proteins with immunity-related roles [62]. Other members of the Ly6/PLAUR family have been shown to be involved with proliferation of neutrophils [63] and to be able to activate transcription factors like activator protein 1 (AP-1) [64], which regulates gene expression and controls a number of cellular processes including differentiation, proliferation, and apoptosis [65]. However, no studies on the possible functions of Lypd8 existed, until very recently, when Okumura et al. showed that Lypd8 is selectively expressed in intestinal epithelial cells and its product is capable of preventing flagellated bacteria from invading the colonic epithelium in mice [66]. Our microarray results clearly indicated that Lypd8 expression was upregulated in A7r5 VSMCs upon activation of α2B-adrenoceptors, suggesting that the functions of this gene would not be restricted solely to the intestine. However, the possible role of Lypd8 in the regulation of A7r5 VSMC proliferation remains to be elucidated.

According to our results, upregulation of Egr1, F3, Ptgs2, cdc20, Serpine1, Kif20a, ube2c and Diaph3 was associated with α2B-adrenoceptor-evoked proliferation of A7r5-α2B cells. All of these genes have previously been implicated in the regulation of VSMC proliferation and also proliferation of several non-vascular cell types. In line with our results, Egr1 seems to be essential for proliferation in many, but not all, cell types [67] and its expression levels often closely correlate with cell proliferation [6870]. Increased Egr1 expression is detected in different vascular pathophysiological processes which involve increased vascular cell proliferation [20] and Egr1 seems to be crucial for effective vascular cell cycle progression in arteriogenesis [71]. Tissue factor F3 is constitutively expressed in VSMCs but it can be upregulated by growth factors and other stimuli [72]. It may contribute to cardiovascular diseases e.g. by inducing proliferation and migration of VSMCs [7375]. VSMC proliferation has been associated with upregulated F3 expression [76], whereas F3 knockdown has led to inhibition of proliferation and increased apoptosis [77]. Ptgs2 directly promotes VSMC proliferation through upregulated gene expression [78], but also by mediating growth-promoting responses to such compounds as angiotensin II and tumor necrosis factor [7981]. Consistently, decreased expression of Ptgs2 is associated with decreased VSMC proliferation and inhibition of cell migration [8284]. Cdc20 is an important cell cycle regulator for the completion of mitosis. In many cancer cell lines, its knockdown inhibits cell division/proliferation, and cdc20 overexpression greatly promotes cell division/proliferation [85, 86]. Also in proliferating human mesenchymal stem cells, cdc20 was upregulated by more than three-fold [87]. So far, little is known about the effects of cdc20 expression on the proliferation of VSMCs. Our results now suggest that increased cdc20 expression could have a growth-promoting effect also in VSMCs. In the literature, a rather uniform impression exists that Serpine1 expression promotes the proliferation of VSMCs [8893], which is in good agreement with our results.

Also Kif20a, ube2c and Diaph3 were upregulated in association with increased A7r5 cell proliferation, but these genes did not receive many annotations in the functional analyses. Interestingly, in proliferating human mesenchymal stem cells, selected cell cycle-related genes that were upregulated more than three-fold included Kif20a, ube2c and cdc20 [87] and, in sheep carotid arteries, ube2c and Diaph3 were highly upregulated during early life and were associated with growth and proliferation [94]. Knockdown of Kif20a suppressed the proliferation of different cancer cell lines [95, 96]. Silencing of ube2c inhibited VSMC proliferation, whereas increased ube2c levels increased VSMC proliferation [97].

The proliferation of VSMCs is not only enhanced by upregulation of growth-promoting genes but also by downregulation of genes with antiproliferative effects. Nppb, Cav1, Tpm1 and Rhoa represent such genes in our dataset; the decreased expression of these genes was associated with increased proliferation of A7r5-α2B cells. Natriuretic peptides, including Nppb, have potent antiproliferative and antimigratory effects on VSMCs [98101], which supports our observation of downregulated Nppb in response to α2B-adrenoceptor activation and the concomitant increase in A7r5-α2B cell proliferation. Also, decreased Cav1 expression has been reported to be associated with proliferating VSMCs [102106] and Tpm1 has been shown to be involved in the microRNA-induced proliferation of VSMCs; increased expression of Tpm1 has inhibited VSMC proliferation [107]. In line with our observations of decreased Rhoa expression and increased cell proliferation is the observation of Tseliou et al. who showed that knockdown of Rhoa in cytomegalovirus-infected human cell lines restored their proliferation rate [108]. However, in contrast with our results, there are many studies reporting that suppression or downregulation of Rhoa leads to inhibited proliferation of VSMCs [109114]. These differences may perhaps be attributed to the existence of many different environmental signals affecting Rhoa signaling and to inherent differences in Rhoa signaling in different cell types [115]. Moreover, a common feature of the Cav1, Tpm1 and Rhoa genes is that their expression has been related to the differentiated, contractile phenotype of VSMCs rather than the proliferative, noncontractile VSMC phenotype [106, 107, 115120]. Caveolae are less abundant in proliferating SMCs than in contractile, nonproliferating cells [121], and Cav1 is more likely to mediate contractile as opposed to proliferative stimulation in smooth muscle [117, 122125]. Rhoa and Tpm1 seem to be important in regulating VSMC contraction and actin reorganization [38, 119, 126, 127], which are functions of the differentiated, nonproliferative phenotype. Tpm1 has even been suggested to be a better phenotypic marker for quiescent VSMCs than the traditional markers smooth muscle α-actin and myosin heavy chain [107, 120]. Considering all this, it is reasonable that these genes are downregulated in proliferating VSMCs as seen in our study.

Thus, for most of the differentially regulated genes associated with α2B-adrenoceptor-evoked proliferation of A7r5 VSMCs, there is strong evidence in the published literature supporting our results. However, for Glrx, Cx3cl1, ccl2, ICAM-1 and Prrx1, our observations differ from what has been previously reported. For Glrx and Cx3cl1, up- and downregulation, respectively, were even confirmed with RT-PCR. Contrary to our results, where upregulation of Glrx was associated with increased proliferation of A7r5 VSMCs, upregulation of Glrx has been linked to decreased proliferation of A7r5 VSMCs, as reported by Urata et al. [128]. In pulmonary artery SMCs and in human lung cancer tissue, Glrx expression showed an inverse correlation with proliferation [129, 130]. At the same time, Glrx may play a role in protecting cells from apoptosis [131]; therefore, its role in cardiovascular functions may not be entirely straightforward, as responses may be dependent upon cell type and extracellular stimuli [132]. This may explain the differences between our results and the literature.

In our results, downregulation of Cx3cl1, ccl2, ICAM-1 and Prrx1 was associated with increased proliferation. Contrary to our results, there is solid evidence indicating that Cx3cl1 and ccl2 may induce VSMC proliferation [133144]. Until now, there is only one report suggesting that ccl2 inhibits VSMC proliferation [145]. Increased expression of ICAM-1 has been associated with increased proliferation of microvascular endothelial cells [146], and it may also promote the proliferation of fetal VSMCs [147]. On the other hand, it has also been reported that ICAM-1 does not contribute to SMC proliferation [148]. Similarly, overexpression of Prrx1 has been reported to promote VSMC proliferation [149, 150]. Cx3cl1, ccl2 and ICAM-1 are induced by inflammatory cytokines [133, 146, 151155]. The pro-proliferative effects of these genes/proteins may be mediated through a pro-inflammatory signaling pathway, whereas the α2B-adrenoceptor-evoked proliferation response, as seen in this study, would be mediated through another mechanism not requiring Cx3cl1 or ccl2. Furthermore, increased expression of ICAM-1 has been detected in differentiated contractile VSMCs [156], and Prrx1 has been shown to regulate SMC differentiation marker genes in fully differentiated VSMCs [115, 157159]. This is in line with these genes being downregulated in proliferating VSMCs, as seen in our study.

Some of the observed effects may have been indirect and evoked by interactions of the differentially expressed genes altering the expression of other genes. For example, Egr1 is an important activator of various proliferation-associated genes such as cdc20 [160, 161], and consistent with this, both Egr1 and cdc20 were upregulated in our results. Furthermore, increased expression of Glrx or Ptgs2 can limit the expression of ICAM-1 in VSMCs [131, 153], and in line with this, Glrx and Ptgs2 were upregulated and ICAM-1 was downregulated in our experiment.

Classically, α2B-adrenoceptors couple to inhibitory Gi/o-type G-proteins leading to inhibition of adenylyl cyclase activity and decreased cyclic AMP (cAMP) levels [162], but this receptor is also capable of coupling to stimulatory Gs-proteins, activating adenylyl cyclases and increasing cAMP levels [50, 163]. Some of the differentially regulated genes may be regulated by cAMP. cAMP can inhibit VSMC proliferation by inhibiting Egr1 expression [20] or the expression of other pro-mitogenic genes by inhibiting Rhoa activity [164]. Ptgs2 induction is known to regulate VSMC proliferation but the effect depends on several factors including the coupling of cAMP to either growth-inhibitory or growth-promoting pathways [165]. Decreased cAMP levels could provide an explanation for the upregulation of Egr1 and Ptgs2 and the concomitant increase in A7r5 VSMC proliferation, but this explanation would not be applicable for Rhoa.

Kinase/phosphatase inhibitor library screening

Protein phosphorylation regulates most processes in eukaryotic cells, and abnormal phosphorylation often is a cause or consequence of disease. Reversible protein phosphorylation requires not only protein kinases to phosphorylate specific serine, threonine or tyrosine residues of target proteins but also protein phosphatases to remove these phosphates [166]. Protein kinases form a big group of structurally related enzymes that participate in mediation of signal transduction in virtually all cellular processes, including cell growth and differentiation [167]. To explore the signaling pathways mediating α2B-adrenoceptor-evoked VSMC proliferation, A7r5-α2B cells were subjected to screening with an 84-compound chemical library consisting of commercially available kinase and phosphatase inhibitors. The effects of different inhibitors on α2B-adrenoceptor-evoked cell proliferation were monitored with a method using BrdU incorporation as readout [168], an assay that measures the amount of newly synthetized DNA [169].

Issues that complicate the use of commercially available enzyme inhibitors may include poor solubility, general toxicity and lack of specificity [170], and inhibitors may give inconsistent results because of the complexity of the involved pathways. Still, inhibitors are valuable tools to study the biology and therapeutic potential of specific kinases. In addition to the limited selectivity of many kinase inhibitors, intracellular signaling pathways contain such redundancy that single drugs might not be able to overcome the robustness of biological networks [171, 172]. A given receptor may mediate its effects through several different signaling mechanisms, and parallel mechanisms may compensate for the effects of a blocked signaling route. This might provide an explanation also in our case, where no single mechanism could be pinpointed as the key regulator of the drug effects. BrdU incorporation was inhibited by less than 30% even with the most effective inhibitors.

We were able to identify several compounds that had statistically significant inhibitory effects on the dexmedetomidine-evoked proliferation of A7r5-α2B cells. We identified several kinases and phosphatases that have been implicated in the promotion of VSMC proliferation, which gives biological credibility to our results. Kinases and phosphatases possibly promoting the mechanisms by which α2B-adrenoceptor activation leads to increased proliferation of A7r5 VSMCs included calcineurin [61, 173175], protein kinase CK2 (casein kinase) [176], Src kinases [177182], JNK [183, 184], p38 MAP kinase [185187], Cdk1/2 [85, 188191], PI3-kinases [173, 192195], EGFR [179, 196199] and Raf-1 kinase [37, 177, 200]. A more detailed description of the effects of these kinases on VSMC proliferation is summarized in Additional file 5. Our results underline the importance of kinases and their interactions in the regulation of VSMC proliferation, since it was impossible for any single inhibitor to overcome the robustness of the cellular signaling networks and completely block the proliferation response.

Kinase activity profiling

Information about substrate proteins is required to integrate kinases into their biological signaling networks [201, 202]. Peptide arrays that monitor kinase activity in cell lysates can be used for the analysis of the kinome and for drug screening purposes [202, 203]. Spotting consensus substrate peptides for kinases on a solid support, incubation with cell lysates and detection with radioactive or fluorescent antibodies makes it possible to determine the kinases that are active in the assay system. Multiplexed treatment of peptide microarrays with cell lysates generates snapshots of the actual phosphorylation equilibrium within cells and reflects the activity of kinases and phosphatases. This should facilitate novel approaches based on phosphorylation fingerprints [202].

To screen for kinases participating in the α2B-adrenoceptor-mediated regulation of VSMC proliferation, we performed kinase activity profiling experiments with PamChip microarrays for protein tyrosine kinases (PTK) and serine/threonine kinases (STK), consisting of altogether 288 target peptide sequences (Additional file 8). We aimed to explore both primary kinase responses at time points < 30 min and secondary kinase responses at later time points after stimulation of A7r5-α2B cells with dexmedetomidine. Treatment effects on kinase signaling were most pronounced at 30 min, where decreased phosphorylation of altogether 40 peptides (36 and 4 on the PTK and STK chips, respectively) was seen. We postulate that at the 30 min time point the A7r5-α2B cells may be in a state of metabolic perturbation, still recovering from contraction caused by dexmedetomidine-induced activation of α2B-adrenoceptors. α2B-adrenoceptor activation leads to rapid and transient myosin light chain (MLC) phosphorylation at Ser19 (pMLC), which is the hallmark biochemical event leading to contraction, peaking at 20-45 s and returning to baseline levels by 2 minutes [58]. However, when the contraction-inducing agonist is not removed, pMLC can be further phosphorylated at Thr18 (ppMLC) [204209]. MLC diphosphorylation does not increase the contractile force but it slows down the relaxation of arterial smooth muscle [210]. By means of live cell microscopy, we have observed that A7r5 VSMC contractions may last at least 20 min when the contraction-inducing agonist is not removed. Additional files 9 and 10 contain time-lapse movies showing typical time-courses of vasopressin-induced contraction of wild-type A7r5 cells and their relaxation after removal of the agonist. This could provide a possible explanation for the overall decrease in kinase activity at 30 min. Thus, the observed overall inhibition of kinase activity might not be directly evoked by α2B-adrenoceptor activation, but is more likely to represent indirect effects caused by other signaling mechanisms.

By 2 h, no differences in kinase activities between dexmedetomidine-stimulated and vehicle-treated cells could be observed, suggesting that by this time the cells had recovered from the contraction and returned to a basal state. Still later, after 24 h of exposure to dexmedetomidine, kinase activities were increased to some extent compared to baseline. However, it remains unclear whether the peak of kinase activity had taken place between 2 h and 24 h, or whether we saw the beginning of increasing overall kinase activity at 24 h. The stability of dexmedetomidine in cell culture medium over a period of 24 h was confirmed by means of quantitative mass spectrometry. In retrospect, the selected time points might not have been optimal. Additional time points at e.g. 12 h and 36 h could have provided an answer to this question.

Only six out of 144 peptides on the STK chip showed differential phosphorylation after treatment with dexmedetomidine. This paucity of effects on Ser/Thr versus tyrosine kinase activities was not unexpected; tyrosine kinase signaling, as monitored by the PTK chip, is more typical for neurotransmitter receptors than Ser/Thr signaling [182, 211, 212]. Although GPCRs do not use tyrosine phosphorylation as a direct mechanism of transmembrane signaling, activation of downstream non-receptor tyrosine kinases upon GPCR activation is important for mitogenic signaling [211, 212]. The subsequent canonical pathway and upstream kinase analyses were thus mostly driven by the kinase activity results obtained from the PTK chip, but also the STK chip results were included. Canonical pathway analysis revealed ten statistically highly significant pathways (−log(p) < 7) at the 30 min time point, but at the 24 h time point, no pathway reached a -log(p) value <4, and thus, their significance is questionable. Therefore, we focus on discussing the significant pathways detected at t = 30 min. Canonical pathway maps are based on recognized connections between signaling pathway components and other pathways appearing in particular cell types and represent a set of signaling and metabolic maps in a comprehensive manner [213]. The traditional views of signaling pathways have been challenged by at least two recent developments; first, a massive increase in the number of components linked to a particular pathway, and second, an appreciation of the variable quantitative contributions of each of these components to dynamic signal propagation [213]. Signal transduction analysis should perhaps pay more attention to recurring signaling cascades in different pathway maps rather than to try to identify entire pathways where only a few kinases seem to be involved.

The c-Raf-1-MEK1-MEK2 signaling cascade appeared in most of the top ten significant pathways; c-Raf-1 phosphorylates MEK1 and MEK2, and dexmedetomidine treatment (30 min) decreased the activity of these kinases. The c-Raf-1-MEK-ERK pathway is one of the best characterized MAP kinase signaling pathways known to regulate cell proliferation [37]. Inhibition of this pathway after 30 min of dexmedetomidine exposure gives support to our hypothesis of the cells being in a state of metabolic perturbation after the initial α2B-adrenoceptor-evoked contraction. Interactions of PLCγ with the PDGF receptor or Epo-receptor, LAT or Syk appeared in many of the significant pathways. In addition, EGFR and the kinases PDK and Fer appeared in many of the significant pathways. It is known that many receptor tyrosine kinases, including PDGFR, Epo-receptor and EGFR, directly phosphorylate and activate PLCγ [214217]. Also, interactions with LAT [218] and Syk [219, 220] have been shown to be required for PLCγ activation. In our peptide array, 30 min exposure to dexmedetomidine significantly decreased the phosphorylation activity of all of these receptor tyrosine kinases and cytosolic protein tyrosine kinases. Actually, it has been shown that α2-adrenoceptors can activate PLC signaling, but such PLC activation is not in itself sufficient to induce a mitogenic response. Preceding activation of Na+/H+ exchange and early gene expression may be involved [14, 221]. Although the PTK chip did not contain a peptide substrate for Lyn kinase, it appears that Lyn kinase activity was also modulated by dexmedetomidine, because Syk, LAT and PLCγ are successive downstream targets in the Lyn signaling cascade (Immune response_Fc epsilon RI pathway, see Additional file 11) and all of these downstream targets showed decreased activity after dexmedetomidine treatment. Moreover, Lyn was also identified as a putative upstream kinase in the upstream kinase analysis, which utilizes different databases than the canonical pathway analysis, includes known phosphorylation sites and is altogether more specific. The finding that different database approaches point in the same direction gives more confidence in the results, and inhibition of Lyn kinase activity appears to affect many downstream kinases.

Five tyrosine kinases, i.e. Frk, Tec, PECAM-1, Cdk2 and Epo-receptor, that were first inhibited after 30 min dexmedetomidine treatment showed increased activity after 24 h of dexmedetomidine stimulation. All five have been implicated in promoting proliferation of different types of cells [191, 222228]. In our system, these kinases showed distinct temporal regulation patterns: inhibition during a suggested initial phase of metabolic perturbation (t ≤ 30 min), followed by increased activity when the cells had reached a phase of active proliferation (t = 24 h).

To further explore the possible signaling mechanisms involved in α2B-adrenoceptor-evoked proliferation of A7r5-α2B VSMCs, a putative upstream kinase analysis was performed to link differentially phosphorylated peptides to the upstream kinases possibly causing the phosphorylation. Several of the upstream kinases that showed decreased activity at 30 min were identified as putative upstream kinases also at 24 h when activation of kinase signaling was detected. These kinases included the receptor kinases HGFR (MET), EGFR, VEGFR-1 (Flt1) and VEGFR-2 (KDR), and the cytosolic kinases ABL2 and Bmx, which also had the highest specificity scores (Additional file 7) among the putative upstream tyrosine kinases. ABL2 promotes proliferation of breast cancer cells and recombinant 293 T cells [229, 230], and Bmx is involved in angiogenesis [231] and in regulation of the actin cytoskeleton and cell motility [232]. Based on our results, these kinases may have similar roles in the regulation of VSMC proliferation. Putative upstream Ser/Thr kinases with the highest specificity scores included CaMK4 and serine/threonine protein kinase 1 (PSKH1), both of which have been implicated in the regulation of cell proliferation [233235]. Moreover, CaMK4 has been identified as an important regulator of pulmonary artery vascular remodeling [236]. Thus, our finding of CaMK4 involvement in regulation of VSMC proliferation derives support from previous observations.

We identified several kinases that have been implicated in regulation of cell growth and proliferation, which gives biological significance to our study. The following growth factors and growth factor receptors appeared as putative upstream regulators in the DNA microarray and/or kinase activity profiling data analyses: bFGF, PDGF, EGFR, HGFR, VEGFR-1 and VEGFR-2 (KDR). PDGF, bFGF and HGF were identified as potential upstream regulators of 7, 9 and 11 genes in our dataset, respectively. EGFR, HGFR, as well as VEGFR-1 and VEGFR-2, were among the top ten putative upstream kinases (showing increased activity at 24 h) in the upstream kinase analysis. Moreover, EGFR was also identified as a potential target kinase in the inhibitor library screening. It not unexpected that growth factors and growth factor receptors appeared among the upstream regulators in the signaling pathways related to promotion of proliferation.

While bFGF and PDGF are known to induce VSMC proliferation [237240], little is known about the possible interactions of α2B-adrenoceptors with bFGF- or PDGF-dependent mechanisms. β-adrenoceptor activation has increased the expression of both of these growth factors [241]. AngII promotes VSMC hypertrophy and endogenous bFGF expression, but increased bFGF expression alone was not sufficient to stimulate VSMC growth; also PKC activation was required [242]. EGFR transactivation by GPCRs can activate multiple mitogenic pathways. Mediators such as Src kinases, Ca2+, PKC and PKA may participate in this process, and especially activation of the EGFR-MAPK pathway is commonly involved in regulation of gene expression and cell proliferation [243, 244]. α2-Adrenoceptors are capable of activating MAP kinases through EGFR transactivation in different cell types including astrocytes [245], renal tubular cells [12], intestinal epithelial cells [45], Müller cells [246] and PC12 cells [46]. The intensity and duration of EGFR transactivation and subsequent MAP kinase activation may control the switching between cell proliferation and alternative fates such as differentiation [247250]. HGF and its receptor HGFR regulate normal cell growth and development in many tissue types, but they also control growth, invasion and metastasis of cancer cells [251254]. HGFR may be transactivated by both EGFR and many GPCRs [255]. HGF/HGFR signaling is activated in angiogenesis [254], and may be involved in the pathogenesis of atherosclerosis and restenosis [256]; HGFR is expressed on VSMCs isolated from atherosclerotic plaques and it triggers signaling cascades (involving PI3-kinases, Akt, MEK and Erk1/2) mediating migration of VSMCs [256, 257]. The VEGF/VEGFR signaling pathway, and especially VEGFR-2, is vital for the induction of angiogenesis and drives both endothelial cell proliferation and migration [258260]. VEGF/VEGFR signaling may have complex effects on VSMC proliferation: a VEGF-mediated pathway has been implicated in the promotion of VSMC proliferation [261, 262], but VEGF/VEGFR-2 has also been identified as a negative regulator of VSMCs [260]. VEGF also appears to be a potent stimulator of VSMC migration [263]. Both α2- and β-adrenoceptors have been reported to regulate VEGF/VEGFR expression [264]. VEGFR-1 is coexpressed with α2B-adrenoceptors in the mouse placenta and, in a knockout mouse model, deletion of the gene encoding α2B-adrenoceptors resulted in upregulation of VEGFR-1 and severely impaired placental angiogenesis [265]. VEGFR-1 has been identified as an antiangiogenic regulator, binding VEGF with high affinity and preventing it from activating other receptor subtypes, including VEGFR-2 [266]. Based on the results of our upstream regulator analyses, many growth factors and growth factor receptors appear to be activated upon sustained (24 h) exposure to dexmedetomidine. The results suggest that α2B-adrenoceptors may mediate their pro-proliferative effects in A7r5 VSMCs by promoting the activity of endogenous bFGF and PDGF and the growth factor receptors EGFR, HGFR and VEGFR-1/2.

Even if our analysis found weaker evidence for Ser/Thr kinase involvement in the regulation of VSMC proliferation by α2B-adrenoceptors than for tyrosine kinase involvement, the putative identified upstream Ser/Thr kinases included relevant actors such as the PKC isoforms δ, γ and Ɛ and the beta adrenergic receptor kinases 1 and 2 (BARK1/Grk2, BARK2/Grk3). These, too, may be involved in the observed activation of kinase signaling after 24 h of exposure to dexmedetomidine. PKC activity modulates several processes in VSMCs, including contraction, growth and proliferation [267269]. PKC has been shown to exert both proliferative and antiproliferative effects on cultured VSMCs [267]. Activation of PKC and, concomitantly, Erk1/2 has been implicated in VSMC proliferation induced by different stimuli, such as AngII [270272], high glucose [273], PDGF-BB and noradrenaline [274]. Several PKC isoforms have been identified in VSMCs. The opposing effects of different PKC isoforms [267, 268, 275279] emphasize the complexity of regulation of VSMC proliferation. A possible mechanism related to the proliferation response caused by α2B-adrenoceptor activation could be mediated through pathways involving regulating the activity of PKC isoforms. Moreover, IPA identified PKC isoforms as potential upstream regulators of gene expression upon α2B-adrenoceptor activation (Fig. 4B). Six genes in our gene array dataset were identified as possibly regulated by PKC isoforms, and for five of these, the observed change in gene expression was in the same direction as predicted.

GPCR signaling may be attenuated by Grk2-mediated desensitization. Also, Grk2 appears to inhibit VSMC proliferation responses to many GPCR agonists and also to PDGF, but not EGFR-mediated VSMC proliferation [280, 281]. Prolonged exposure of α2B-adrenoceptors to agonists results in downregulation of the receptors [282], mediated by both Grk2 and Grk3 [47]. Although little is known of the effects of Grk3 on VSMC proliferation, it has been established that Grk3 plays an important role in the survival and proliferation of metastatic prostate cancer cells and in stimulation of tumor angiogenesis [283, 284]. Based on this, we are tempted to speculate that the signaling mechanisms of the α2B-adrenoceptor-evoked proliferation response in A7r5 VSMCs could involve transactivation of EGFR, which is not affected by the inhibitory effects of Grk2, and that increased activities of Grk2 and Grk3 after 24 h of dexmedetomidine treatment could be a counteracting mechanism leading to α2B-adrenoceptor downregulation and attenuation of the α2B-adrenoceptor-evoked proliferation response.

Comparison of the employed screening methods

A secondary aim of the present study was to evaluate the suitability of three different in vitro screening approaches to investigate gene expression patterns and intracellular signaling pathways related to α2B-adrenoceptor-evoked VSMC proliferation. We identified several gene products/kinases that appeared as top hits in two out of the three screens. HGF/HGFR and isoforms of PKC appeared as hits in the DNA microarray and in the kinase activity profiling. Raf-1, EGFR, Src kinases and the MAP kinases p38 and JNK appeared as hits in the inhibitor library screening and in the kinase activity profiling. The roles of HGF/HGFR, PKC and EGFR in the regulation of VSMC proliferation have already been discussed. It is well established that also Raf-1, Src kinases, p38 and JNK kinases participate in the regulation of VSMC proliferation [177, 178, 183, 185187, 285, 286], but due to space limitations we will not discuss this in more detail here. That these kinases were identified as hits by two different screening methods increases the confidence level of the results. However, these results are only preliminary and should be regarded as starting points for more detailed analysis employing cell models, kinase inhibitors and different cell-based assays.

Each of the employed screening methods has its own advantages and disadvantages. Gene microarrays enable the analysis of mRNA expression levels and are of significant value for the elucidation of molecular mechanisms that govern cellular physiology [201]. Still, very critical transcripts may be expressed at low levels [287, 288] and small changes in gene expression can lead to large changes in the cell phenotype and function. Indeed, a comprehensive description of cellular metabolism and intracellular signaling might provide more useful information than gene expression analysis alone. To some extent, monitoring of cellular functions can be achieved by kinase activity analysis. Peptide microarrays have emerged as promising tools for the analysis of protein functions and kinase activity [31, 33, 203, 289291]. The employed PamChip kinase activity profiling technology is relatively new. The kinase substrates on the PamChips are peptides consisting of 13–14 amino acids and may have similarities with other substrates, which makes cross-reactivity possible. However, other investigators have validated their PamChip results by Western blot analysis and demonstrated that kinase inhibitors affected peptide array phosphorylation patterns consistently with the expected actions of these inhibitors [292, 293].

In the present study, DNA microarray and kinase activity profiling were technically successful and of high experimental quality. As for the kinase/phosphatase inhibitor library screening, the obtained results showed large variability and, consequently, the screen failed to reach a z’ score of 0.5, indicating limited robustness. Nevertheless, also the inhibitor library screen has advantages; many different readouts can be employed to evaluate inhibitor effects and data analysis is very straightforward. We employed α2B-adrenoceptor-evoked cell proliferation as the readout for evaluating kinase inhibitor effects by measuring BrdU incorporation. Individual test compounds did not have very large inhibitory effects on the proliferation response, demonstrating that compensatory signaling mechanisms exist and that it may be difficult for a single kinase inhibitor to overcome the robustness of biological networks. Furthermore, kinase inhibitors often lack specificity and a kinase inhibitor will often inhibit multiple related proteins making it difficult or impossible to define the specific functions of an individual target [294]. Hence, the goal of inhibitor screening in general should not be full reconstruction of a regulatory network, but rather to identify a set of kinases linked to a specific response in a given cell line. Then, the hypotheses derived from results such as those presented here need to be validated by further experiments with different inhibitors for the same target or with alternative methods, e.g. using siRNA silencing technology [172].

Peptide arrays, such as the PamChip kinase activity profiling technology, represent a more comprehensive approach to the investigation of kinase signaling compared to traditional genetic and biochemical approaches, which for technical and practical reasons are typically pursued for one gene or pathway at a time. Moreover, peptide arrays of kinase-specific substrates are incubated with cell lysates, allowing analysis of cellular signaling without a priori assumptions of the pathways possibly influenced [295]. Their simplicity and high throughput make peptide microarrays especially suitable for practical applications; monitoring of drug effects on cellular kinomics as a tool for drug development, and for kinomics-based diagnostics and prognosis evaluation of diseases [296]. That eukaryotic protein kinases form a large superfamily of homologous proteins and that their kinase domains (catalytic domains) are fairly conserved [297] makes peptide arrays suitable for the analysis of cell lysates independent of their origin and species. This is a great advantage compared to DNA microarrays, where arrays are performed on species-specific chips.

Conclusions

α2B-adrenoceptor activation stimulates VSMC proliferation, and this may be important for the development and plasticity of blood vessels and for the pathology and therapeutics related to different cardiovascular disorders and even neoangiogenesis of tumors. However, the underlying cellular mechanisms and signal transduction pathways have remained mostly unknown. In this study, we employed three different approaches to investigate changes in gene expression, signaling pathways and kinase activation profiles related to α2B-adrenoceptor-regulated VSMC proliferation. Based on the results of this study, the cellular mechanisms participating in this proliferation response appear to be complex and include redundancy. Differentially regulated genes that were identified by two different functional analyses (GeneFuncster and IPA) included Egr1, Ptgs2, Cx3cl1, Cav1 and Nppb. This provides further support for the already claimed involvement of these genes in the regulation of VSMC proliferation. Our analysis also suggested the involvement of other genes, such as F3, Serpine1, Rhoa and Prrx1 that are known to play important roles in the regulation of SMC-specific functions including migration, adhesion and contraction. Nevertheless, also some surprise findings were encountered. Indeed, the most highly upregulated gene in our dataset, Ly6/PLAUR domain containing 8 (Lypd8) did not receive any annotations in the functional analyses. Lypd8 belongs to the Ly6/PLAUR family of proteins. Members of the Ly6/PLAUR family activate transcription factors to regulate gene expression and processes such as differentiation, proliferation, and apoptosis. Lypd8 has been reported to be selectively expressed in intestinal epithelial cells, but our microarray results clearly indicated that Lypd8 expression was upregulated in A7r5 VSMCs upon activation of α2B-adrenoceptors, suggesting that the functions of this gene might not be restricted to the intestine.

A given receptor may mediate its effects through several different signaling mechanisms, and parallel mechanisms may compensate for the effects of a blocked signaling route. This redundancy might provide an explanation for our kinase/phosphatase inhibitor results, where no single mechanism could be pinpointed as the key regulator of VSMC proliferation. Agonist-stimulated DNA synthesis was inhibited by less than 30% by the most effective enzyme inhibitors. The results suggested involvement of several kinases that have already been implicated in the promotion of VSMC proliferation. Identified kinases possibly promoting α2B-adrenoceptor-mediated VSMC proliferation included protein kinase CK2, Src kinase, JNK, p38 MAP kinase, Cdk1/2, PI3-kinases, EGFR and Raf-1 kinase. The results underline the importance of kinases and their interactions in the regulation of VSMC proliferation. It was impossible to overcome the robustness of the involved biological signaling networks with any single inhibitor and to completely block the proliferation response.

Identified putative upstream tyrosine kinases included the cytosolic kinases ABL2 and Bmx, and several growth factors and growth factor receptors, such as bFGF, PDGF, EGFR, HGFR, VEGFR-1 and VEGFR-2. All of these growth factors/growth factor receptors have been implicated in regulation of VSMC proliferation, which supports the biological significance of the present findings. Our results suggest that α2B-adrenoceptors may mediate their pro-proliferative effects in VSMCs by promoting the activity of endogenous bFGF and PDGF and the growth factor receptors EGFR, HGFR and VEGFR-1/2. As a more novel finding, the Src family kinase Lyn was identified by us as a putative upstream kinase. Its involvement was suggested by two different pathway analysis approaches. Lyn is known to be expressed in VSMCs [298, 299], to be regulated by pertussis toxin-insensitive GPCR signaling [300], and has been identified as an important regulator of GPCR trafficking and their effects on cell proliferation [301, 302]. Identified putative Ser/Thr kinases included some biologically relevant kinases such as several PKC isoforms and the β-adrenergic receptor kinases 1 and 2 (Grk2 and Grk3). Cross-talk between the signaling mechanisms involved in α2B-adrenoceptor-evoked VSMC proliferation thus appears to involve PKC activation, subsequent changes in gene expression, transactivation of EGFR, and modulation of kinase activities and growth factor-mediated signaling.

Pathway analysis and upstream kinase analysis emerged as useful approaches, as also relatively weak signals could be identified, and they provided a broader overview of the signaling events within the cell compared with targeted experiments on individual genes or kinases. Still, any direct mechanistic conclusions about an observed effect should be made with appropriate caution, as the observed changes could be either causes or consequences of the proliferation response. We conclude that the employed screening tools are useful for hypothesis generation, but hypothesis testing will require additional approaches, such as overexpression cell models or gene silencing with e.g. siRNA technology.

Declarations

Acknowledgements

We thank Mrs. Ulla Uoti and Mrs. Hanna Haukkala for skillful technical assistance.

Funding

This work has been financed by the University of Turku Graduate School’s Drug Research Doctoral Program, the Finnish Cultural Foundation, the Paavo Nurmi Foundation, the Finnish Heart Foundation, the Urho Känkänen Foundation, the Turku University Foundation, the Magnus Ehrnrooth Foundation, the Otto A. Malm Foundation and TYKSLAB.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Authors’ contributions

AH and MS designed the study. AH performed all cell culture work, prepared all samples and analyzed data. AL analyzed and interpreted the DNA microarray data and contributed to the writing of this section of the manuscript. AH and VH performed the small compound library screening and VH contributed to the writing of this section of the manuscript. EL performed the statistical analysis of the small compound library screening data. DP analyzed and interpreted the kinase activity profiling data and contributed to the writing of this section of the manuscript. AH authored the manuscript together with MS. All authors read and approved the final manuscript.

Competing interests

The authors declare that they do not have competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku
(2)
Toxicology Division, Misvik Biology Oy
(3)
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University
(4)
Department of Biostatistics, Department of Clinical Medicine, University of Turku
(5)
PamGene International BV
(6)
Unit of Clinical Pharmacology, Turku University Hospital

References

  1. Gilsbach R, Hein L. Are the pharmacology and physiology of α2 adrenoceptors determined by α2-heteroreceptors and autoreceptors respectively? Br J Pharmacol. 2012;165:90–102.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273:803–5.PubMedView ArticleGoogle Scholar
  3. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003;99:889–95.PubMedView ArticleGoogle Scholar
  4. Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65–70.PubMedView ArticleGoogle Scholar
  5. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382–94.PubMedView ArticleGoogle Scholar
  6. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science. 1996;273:801–3.PubMedView ArticleGoogle Scholar
  7. Aantaa R, Jalonen J. Perioperative use of alpha2-adrenoceptor agonists and the cardiac patient. Eur J Anaesthesiol. 2006;23:361–72.PubMedView ArticleGoogle Scholar
  8. Bruzzone A, Piñero CP, Castillo LF, Sarappa MG, Rojas P, Lanari C, et al. Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice. Br J Pharmacol. 2008;155:494–504.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Pérez Piñero C, Bruzzone A, Sarappa MG, Castillo LF, Lüthy IA. Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation. Br J Pharmacol. 2012;166:721–36.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Xia M, Tong J-H, Zhou Z-Q, Duan M-L, Xu J-G, Zeng H-J, et al. Tramadol inhibits proliferation, migration and invasion via α2-adrenoceptor signaling in breast cancer cells. Eur Rev Med Pharmacol Sci. 2016;20:157–65.PubMedGoogle Scholar
  11. Vázquez SM, Mladovan AG, Pérez C, Bruzzone A, Baldi A, Lüthy IA. Human breast cell lines exhibit functional alpha2-adrenoceptors. Cancer Chemother Pharmacol. 2006;58:50–61.PubMedView ArticleGoogle Scholar
  12. Cussac D, Schaak S, Gales C, Flordellis C, Denis C, Paris H. Alpha(2B)-adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells. Am. J. Physiol. Renal Physiol. 2002;282:F943–52.View ArticleGoogle Scholar
  13. Kribben A, Herget-Rosenthal S, Lange B, Erdbrügger W, Philipp T, Michel MC. Alpha2-adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition. Naunyn Schmiedeberg's Arch Pharmacol. 1997;356:225–32.View ArticleGoogle Scholar
  14. Seuwen K, Magnaldo I, Kobilka BK, Caron MG, Regan JW, Lefkowitz RJ, et al. Alpha 2-adrenergic agonists stimulate DNA synthesis in Chinese hamster lung fibroblasts transfected with a human alpha 2-adrenergic receptor gene. Cell Regul. 1990;1:445–51.PubMedPubMed CentralGoogle Scholar
  15. Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H, Alpini G. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology. 2002;35:1329–40.PubMedView ArticleGoogle Scholar
  16. Karkoulias G, Mastrogianni O, Ilias I, Lymperopoulos A, Taraviras S, Tsopanoglou N, et al. Alpha 2-adrenergic receptors decrease DNA replication and cell proliferation and induce neurite outgrowth in transfected rat pheochromocytoma cells. Ann N Y Acad Sci. 2006;1088:335–45.PubMedView ArticleGoogle Scholar
  17. Huhtinen A, Scheinin M. Expression and characterization of the human alpha 2B-adrenoceptor in a vascular smooth muscle cell line. Eur J Pharmacol. 2008;587:48–56.PubMedView ArticleGoogle Scholar
  18. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis. Exp Mol Pathol. 1985;42:139–62.PubMedView ArticleGoogle Scholar
  19. Shi N, Chen S-Y. Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res. 2014;28:40–6.PubMedGoogle Scholar
  20. Kimura TE, Duggirala A, Hindmarch CCT, Hewer RC, Cui M-Z, Newby AC, et al. Inhibition of Egr1 expression underlies the anti-mitogenic effects of cAMP in vascular smooth muscle cells. J Mol Cell Cardiol. 2014;72:9–19.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75:487–517.PubMedGoogle Scholar
  22. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801.PubMedView ArticleGoogle Scholar
  23. R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.Google Scholar
  24. The R Project for Statistical Computing [Internet]. [cited 2016 Jul 6]. Available from: https://www.r-project.org/
  25. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Bioconductor Open Source Software for Bioinformatics [Internet]. [cited 2016 Jul 6]. Available from: http://www.bioconductor.org/
  27. Laiho A, Király A, Gyenesei A. GeneFuncster: a web tool for Gene functional enrichment analysis and visualisation. CMSB; 2012. p. 382–5.Google Scholar
  28. Group HB. GeneFuncster [Internet]. [cited 2016 Jul 6]. Available from: http://bioinfo.utu.fi/GeneFuncster
  29. Ingenuity [Internet]. [cited 2016 Jul 6]. Available from: http://www.ingenuity.com/
  30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.PubMedView ArticleGoogle Scholar
  31. Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R. Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples. Methods Mol Biol. 2013;977:259–71.PubMedView ArticleGoogle Scholar
  32. Sikkema AH, Diks SH, den Dunnen WFA, ter Elst A, Scherpen FJG, Hoving EW, et al. Kinome profiling in pediatric brain tumors as a new approach for target discovery. Cancer Res. 2009;69:5987–95.PubMedView ArticleGoogle Scholar
  33. Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R. Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase a. Anal Biochem. 2009;387:150–61.PubMedView ArticleGoogle Scholar
  34. Versele M, Talloen W, Rockx C, Geerts T, Janssen B, Lavrijssen T, et al. Response prediction to a multitargeted kinase inhibitor in cancer cell lines and xenograft tumors using high-content tyrosine peptide arrays with a kinetic readout. Mol Cancer Ther. 2009;8:1846–55.PubMedView ArticleGoogle Scholar
  35. PamGene BioNavigator [Internet]. [cited 2016 Jul 6]. Available from: https://www.pamgene.com/en/bionavigator.htm
  36. PhosphoNET Human Phosphosite KnowledgeBase [Internet]. [cited 2016 Jul 6]. Available from: http://www.phosphonet.ca/
  37. Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002;12:9–18.PubMedView ArticleGoogle Scholar
  38. Baker AH. MicroRNA 21 “shapes” vascular smooth muscle behavior through regulating tropomyosin 1. Arterioscler Thromb Vasc Biol. 2011;31:1941–2.PubMedView ArticleGoogle Scholar
  39. Schwartz SM, de Blois D, O’Brien ER. The intima. Soil for atherosclerosis and restenosis. Circ Res. 1995;77:445–65.PubMedView ArticleGoogle Scholar
  40. Alexander MR, Owens GK. Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol Annual Reviews. 2012;74:13–40.View ArticleGoogle Scholar
  41. Olli-Lähdesmäki T, Tiger M, Vainio M, Scheinin M, Kallio J. Ligand-induced alpha2-adrenoceptor endocytosis: relationship to Gi protein activation. Biochem Biophys Res Commun. 2004;321:226–33.PubMedView ArticleGoogle Scholar
  42. Ge H, Olli-Lähdesmäki T, Kallio J, Scheinin M. Alpha 2B-Adrenoceptor levels govern agonist and inverse agonist responses in PC12 cells. Biochem. Biophys. Res. Communications. 2003;308:12–8.Google Scholar
  43. Olli-Lähdesmäki T, Kallio J, Scheinin M. Receptor subtype-induced targeting and subtype-specific internalization of human alpha(2)-adrenoceptors in PC12 cells. J Neurosci. 1999;19:9281–8.PubMedGoogle Scholar
  44. Olli-Lähdesmäki T, Scheinin M, Pohjanoksa K, Kallio J. Agonist-dependent trafficking of alpha2-adrenoceptor subtypes: dependence on receptor subtype and employed agonist. Eur J Cell Biol. 2003;82:231–9.PubMedView ArticleGoogle Scholar
  45. Buffin-Meyer B, Crassous P-A, Delage C, Denis C, Schaak S, Paris H. EGF receptor transactivation and PI3-kinase mediate stimulation of ERK by α2A-adrenoreceptor in intestinal epithelial cells: a role in wound healing. Eur J Pharmacol. 2007;574:85–93.PubMedView ArticleGoogle Scholar
  46. Karkoulias G, Mastrogianni O, Lymperopoulos A, Paris H, Flordellis C. α2-adrenergic receptors activate MAPK and Akt through a pathway involving arachidonic acid metabolism by cytochrome P450-dependent epoxygenase, matrix metalloproteinase activation and subtype-specific transactivation of EGFR. Cell Signal. 2006;18:729–39.PubMedView ArticleGoogle Scholar
  47. Desai AN, Salim S, Standifer KM, Eikenburg DC. Involvement of G protein-coupled receptor Kinase (GRK) 3 and GRK2 in down-regulation of the 2B-Adrenoceptor. J Pharmacol Exp Ther American Society for Pharmacology and Experimental Therapeutics. 2006;317:1027–35.PubMedView ArticleGoogle Scholar
  48. Ge H, Scheinin M, Kallio J. Constitutive precoupling to G(i) and increased agonist potency in the alpha(2B)-adrenoceptor. Biochem Biophys Res Commun. 2003;306:959–65.PubMedView ArticleGoogle Scholar
  49. Jansson CC, Pohjanoksa K, Lang J, Wurster S, Savola JM, Scheinin M. Alpha2-adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. Eur J Pharmacol. 1999;374:137–46.PubMedView ArticleGoogle Scholar
  50. Pohjanoksa K, Jansson CC, Luomala K, Marjamäki A, Savola JM, Scheinin M. Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol. 1997;335:53–63.PubMedView ArticleGoogle Scholar
  51. Jeyaraj SC, Chotani MA, Mitra S, Gregg HE, Flavahan NA, Morrison KJ. Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol. 2001;60:1195–200.PubMedGoogle Scholar
  52. Chotani MA, Flavahan S, Mitra S, Daunt D, Flavahan NA. Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000;278:H1075–83.PubMedGoogle Scholar
  53. Chotani MA, Mitra S, Su BY, Flavahan S, Eid AH, Clark KR, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;286:H59–67.PubMedView ArticleGoogle Scholar
  54. Chotani MA, Mitra S, Eid AH, Han SA, Flavahan NA. Distinct cAMP signaling pathways differentially regulate alpha2C-adrenoceptor expression: role in serum induction in human arteriolar smooth muscle cells. Am J Physiol Heart Circ Physiol. 2005;288:H69–76.PubMedView ArticleGoogle Scholar
  55. Eid AH, Maiti K, Mitra S, Chotani MA, Flavahan S, Bailey SR, et al. Estrogen increases smooth muscle expression of α2C-adrenoceptors and cold-induced constriction of cutaneous arteries. Am J Physiol Heart Circ Physiol. 2007;293:H1955–61.PubMedView ArticleGoogle Scholar
  56. Eid AH, Chotani MA, Mitra S, Miller TJ, Flavahan NA. Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha2C-adrenoceptors. Am J Physiol Heart Circ Physiol. 2008;295:H266–72.PubMedPubMed CentralView ArticleGoogle Scholar
  57. Motawea HKB, Blazek AD, Zirwas MJ, Pleister AP, Ahmed AAE, McConnell BK, et al. Delocalization of endogenous A-kinase antagonizes Rap1-rho-α2C-Adrenoceptor signaling in human Microvascular smooth muscle cells. J Cytol Mol Biol. 2014;1:1000002.PubMedPubMed CentralGoogle Scholar
  58. Björk S, Huhtinen A, Vuorenpää A, Scheinin M. Quantitative determination of α(2B)-adrenoceptor-evoked myosin light chain phosphorylation in vascular smooth muscle cells. J Pharmacol Toxicol Methods. Elsevier Inc. 2014;70:152–62.PubMedView ArticleGoogle Scholar
  59. Morey JS, Ryan JC, Van Dolah FM. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR. Biol Proced Online. 2006;8:175–93.PubMedPubMed CentralView ArticleGoogle Scholar
  60. Wang Y, Hou R, Li P, Li J, Yan J, Yin F, et al. Gene expression profiles in response to the activation of adrenoceptors in A7r5 aortic smooth muscle cells. Clin Exp Pharmacol Physiol. 2004;31:602–7.PubMedView ArticleGoogle Scholar
  61. Pang X, Sun N. Calcineurin-NFAT signaling is involved in phenylephrine-induced vascular smooth muscle cell proliferation. Acta Pharmacol Sin. 2009;30:537–44.PubMedPubMed CentralView ArticleGoogle Scholar
  62. LeClair KP, Palfree RG, Flood PM, Hammerling U, Bothwell A. Isolation of a murine Ly-6 cDNA reveals a new multigene family. EMBO J. 1986;5:3227–34.PubMedPubMed CentralGoogle Scholar
  63. Stroncek DF, Caruccio L, Bettinotti M. CD177: a member of the Ly-6 gene superfamily involved with neutrophil proliferation and polycythemia vera. J Transl Med. 2004;2:8.PubMedPubMed CentralView ArticleGoogle Scholar
  64. Ni J, Lang Q, Bai M, Zhong C, Chen X, Wan B, et al. Cloning and characterization of a human LYPD7, a new member of the Ly-6 superfamily. Mol Biol Rep. 2009;36:697–703.PubMedView ArticleGoogle Scholar
  65. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie. 2003;85:747–52.PubMedView ArticleGoogle Scholar
  66. Okumura R, Kurakawa T, Nakano T, Kayama H, Kinoshita M, Motooka D, et al. Lypd8 promotes the segregation of flagellated microbiota and colonic epithelia. Nature. Nature Publishing Group. 2016;532:117–21.PubMedView ArticleGoogle Scholar
  67. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J. 2012;26:1582–92.PubMedPubMed CentralView ArticleGoogle Scholar
  68. Khachigian LM. Early growth response-1 in cardiovascular Pathobiology. Circ Res. 2006;98:186–91.PubMedView ArticleGoogle Scholar
  69. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287–92.PubMedView ArticleGoogle Scholar
  70. Liu Q-F, Yu H-W, You L, Liu M-X, Li K-Y, Tao G-Z. Apelin-13-induced proliferation and migration induced of rat vascular smooth muscle cells is mediated by the upregulation of Egr-1. Biochem Biophys Res Commun. 2013;439:235–40.PubMedView ArticleGoogle Scholar
  71. Pagel J-I, Ziegelhoeffer T, Heil M, Fischer S, Fernández B, Schaper W, et al. Role of early growth response 1 in arteriogenesis: impact on vascular cell proliferation and leukocyte recruitment in vivo. Thromb Haemost. 2012;107:562–74.PubMedView ArticleGoogle Scholar
  72. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, et al. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest. 1997;100:2276–85.PubMedPubMed CentralView ArticleGoogle Scholar
  73. Pyo RT, Sato Y, Mackman N, Taubman MB. Mice deficient in tissue factor demonstrate attenuated intimal hyperplasia in response to vascular injury and decreased smooth muscle cell migration. Thromb Haemost. 2004;92:451–8.PubMedGoogle Scholar
  74. Giannarelli C, Alique M, Rodriguez DT, Yang DK, Jeong D, Calcagno C, et al. Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1α and vascular endothelial growth factor signaling. Circulation. 2014;130:1274–86.PubMedPubMed CentralView ArticleGoogle Scholar
  75. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation. 2006;113:722–31.PubMedView ArticleGoogle Scholar
  76. Yisireyili M, Saito S, Abudureyimu S, Adelibieke Y, Ng H-Y, Nishijima F, et al. Indoxyl sulfate-induced activation of (pro)renin receptor promotes cell proliferation and tissue factor expression in vascular smooth muscle cells. PLoS One. 2014;9:e109268.PubMedPubMed CentralView ArticleGoogle Scholar
  77. Wan K, Li J, Li D, Ge J, Wang Y, Li X, et al. Novel hydroxybutyl chitosan nanoparticles for siRNA delivery targeting tissue factor inhibits proliferation and induces apoptosis in human vascular smooth muscle cells. Mol Med Rep. 2015;12:7957–62.PubMedPubMed CentralGoogle Scholar
  78. Tzeng H-P, Sen YR, Ueng T-H, Liu S-H. Upregulation of cyclooxygenase-2 by motorcycle exhaust particulate-induced reactive oxygen species enhances rat vascular smooth muscle cell proliferation. Chem Res Toxicol. 2007;20:1170–6.PubMedView ArticleGoogle Scholar
  79. Hu Z-W, Kerb R, Shi X-Y, Wei-Lavery T, Hoffman BB. Angiotensin II increases expression of cyclooxygenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 2002;303:563–73.PubMedView ArticleGoogle Scholar
  80. Aguado A, Galán M, Zhenyukh O, Wiggers GA, Roque FR, Redondo S, et al. Mercury induces proliferation and reduces cell size in vascular smooth muscle cells through MAPK, oxidative stress and cyclooxygenase-2 pathways. Toxicol Appl Pharmacol. 2013;268:188–200.PubMedView ArticleGoogle Scholar
  81. Haider A, Lee I, Grabarek J, Darzynkiewicz Z, Ferreri NR. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Circulation. 2003;108:1015–21.PubMedView ArticleGoogle Scholar
  82. Choi HC, Kim HS, Lee KY, Chang KC, Kang YJ. NS-398, a selective COX-2 inhibitor, inhibits proliferation of IL-1beta-stimulated vascular smooth muscle cells by induction of HO-1. Biochem Biophys Res Commun. 2008;376:753–7.PubMedView ArticleGoogle Scholar
  83. Chang C-C, Duann Y-F, Yen T-L, Chen Y-Y, Jayakumar T, Ong E-T, et al. Andrographolide, a novel NF-κB inhibitor, inhibits vascular smooth muscle cell proliferation and cerebral endothelial cell inflammation. Acta Cardiol Sin. 2014;30:308–15.PubMedPubMed CentralGoogle Scholar
  84. Yang H-L, Huang P-J, Liu Y-R, Kumar KJS, Hsu L-S, Lu T-L, et al. Toona Sinensis inhibits LPS-induced inflammation and migration in vascular smooth muscle cells via suppression of reactive oxygen species and NF-κB signaling pathway. Oxidative Med Cell Longev. 2014;2014:901315.Google Scholar
  85. Chen Z, Yu Y, Fu D, Li Z, Niu X, Liao M, et al. Functional roles of PC-PLC and Cdc20 in the cell cycle, proliferation, and apoptosis. Cell Biochem Funct. 2010;28:249–57.PubMedView ArticleGoogle Scholar
  86. Wang L, Zhang J, Wan L, Zhou X, Wang Z, Wei W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther 2015 151:141–151.Google Scholar
  87. Kolosova IA, Angelini D, Fan C, Skinner J, Cheadle C, Johns RA. Resistin-like molecule α stimulates proliferation of mesenchymal stem cells while maintaining their multipotency. Stem Cells Dev. 2013;22:239–47.PubMedView ArticleGoogle Scholar
  88. Jeong IK, Oh DH, Park SJ, Kang JH, Kim S, Lee MS, et al. Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med. 2011;43:684–92.PubMedPubMed CentralView ArticleGoogle Scholar
  89. Samarakoon R, Higgins PJ. Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost. 2008;100:976–83.PubMedPubMed CentralGoogle Scholar
  90. Chen Y, Budd RC, Kelm RJ, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol. 2006;26:1777–83.PubMedView ArticleGoogle Scholar
  91. Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost. 2008;100:1029–36.PubMedPubMed CentralGoogle Scholar
  92. Beauchamp NJ, van Achterberg TA, Engelse MA, Pannekoek H, de Vries CJ. Gene expression profiling of resting and activated vascular smooth muscle cells by serial analysis of gene expression and clustering analysis. Genomics. 2003;82:288–99.PubMedView ArticleGoogle Scholar
  93. Knudsen BS, Harpel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest. 1987;80:1082–9.PubMedPubMed CentralView ArticleGoogle Scholar
  94. Goyal R, Longo LD. Gene expression in sheep carotid arteries: major changes with maturational development. Pediatr Res. 2012;72:137–46.PubMedPubMed CentralView ArticleGoogle Scholar
  95. Shi C, Huang D, Lu N, Chen D, Zhang M, Yan Y, et al. Aberrantly activated Gli2-KIF20A axis is crucial for growth of hepatocellular carcinoma and predicts poor prognosis. Oncotarget. 2016;7:26206–19.PubMedPubMed CentralGoogle Scholar
  96. Stangel D, Erkan M, Buchholz M, Gress T, Michalski C, Raulefs S, et al. Kif20a inhibition reduces migration and invasion of pancreatic cancer cells. J Surg Res. 2015;197:91–100.PubMedView ArticleGoogle Scholar
  97. Tsihlis ND, Oustwani CS, Vavra AK, Jiang Q, Keefer LK, Kibbe MR. Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell Biochem Biophys. 2011;60:89–97.PubMedView ArticleGoogle Scholar
  98. Schirger JA, Grantham JA, Kullo IJ, Jougasaki M, Wennberg PW, Chen HH, et al. Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. J Am Coll Cardiol. 2000;35:796–801.PubMedView ArticleGoogle Scholar
  99. Casco VH, Veinot JP. Kuroski de bold ML, masters RG, Stevenson MM, de bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem. 2002;50:799–809.PubMedView ArticleGoogle Scholar
  100. Nakayama T. The genetic contribution of the natriuretic peptide system to cardiovascular diseases. Endocr J. 2005;52:11–21.PubMedView ArticleGoogle Scholar
  101. Berk BC. Vascular smooth muscle growth: Autocrine growth mechanisms. Physiol Rev. 2001;81:999–1030.PubMedGoogle Scholar
  102. Carrillo-Sepulveda MA, Matsumoto T. Phenotypic modulation of mesenteric vascular smooth muscle cells from type 2 diabetic rats is associated with decreased caveolin-1 expression. Cell Physiol Biochem. 2014;34:1497–506.PubMedView ArticleGoogle Scholar
  103. Luo D, Cheng J, Xiong Y, Li J, Xia C, Xu C, et al. Static pressure drives proliferation of vascular smooth muscle cells via caveolin-1/ERK1/2 pathway. Biochem Biophys Res Commun. 2010;391:1693–7.PubMedView ArticleGoogle Scholar
  104. Mulas MF, Maxia A, Dessì S, Mandas A. Cholesterol esterification as a mediator of proliferation of vascular smooth muscle cells and peripheral blood mononuclear cells during atherogenesis. J Vasc Res. 2014;51:14–26.PubMedView ArticleGoogle Scholar
  105. Schwencke C, Schmeisser A, Walter C, Wachter R, Pannach S, Weck B, et al. Decreased caveolin-1 in atheroma: loss of antiproliferative control of vascular smooth muscle cells in atherosclerosis. Cardiovasc Res. 2005;68:128–35.PubMedView ArticleGoogle Scholar
  106. Williams TM, Lisanti MP. The Caveolin genes: from cell biology to medicine. Ann Med. 2004;36:584–95.PubMedView ArticleGoogle Scholar
  107. Wang M, Li W, Chang G-Q, Ye C-S, Ou J-S, Li X-X, et al. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol. 2011;31:2044–53.PubMedView ArticleGoogle Scholar
  108. Tseliou M, Al-Qahtani A, Alarifi S, Alkahtani SH, Stournaras C, Sourvinos G. The role of RhoA, RhoB and RhoC GTPases in cell morphology, proliferation and migration in human cytomegalovirus (HCMV) infected Glioblastoma cells. Cell Physiol Biochem. 2016;38:94–109.PubMedView ArticleGoogle Scholar
  109. Yu L, Quinn DA, Garg HG, Hales CA. Heparin inhibits pulmonary artery smooth muscle cell proliferation through guanine nucleotide exchange factor-H1/RhoA/rho kinase/p27. Am J Respir Cell Mol Biol. 2011;44:524–30.PubMedView ArticleGoogle Scholar
  110. Hung C-N, Huang H-P, Lii C-K, Liu K-L, Wang C-J. Sulforaphane inhibits smooth muscle cell proliferation and migration by reducing MMP-9 activity via the Ras and RhoA/ROCK pathways. J Funct Foods. 2013;5:1097–107.View ArticleGoogle Scholar
  111. Rigassi L, Barchiesi Bozzolo F, Lucchinetti E, Zaugg M, Fingerle J, Rosselli M, et al. 2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cells. Am J Physiol Endocrinol Metab. 2015;309:E995–1007.PubMedPubMed CentralView ArticleGoogle Scholar
  112. Du C-Q, Liu X-W, Zeng G-Z, Jin H-F, Tang L-J. Inhibition of farnesyl pyrophosphate synthase attenuates angiotensin II-induced fibrotic responses in vascular smooth muscle cells. Int J Mol Med. 2015;35:1767–72.PubMedGoogle Scholar
  113. Croft DR, Olson MF. The rho GTPase effector ROCK regulates cyclin a, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 2006;26:4612–27.PubMedPubMed CentralView ArticleGoogle Scholar
  114. Renteria LS, Austin M, Lazaro M, Andrews MA, Lustina J, Raj JU, et al. RhoA-rho kinase and platelet-activating factor stimulation of ovine foetal pulmonary vascular smooth muscle cell proliferation. Cell Prolif. 2013;46:563–75.PubMedPubMed CentralGoogle Scholar
  115. Mack CP, Hinson JS. Regulation of smooth muscle differentiation by the myocardin family of serum response factor co-factors. J Thromb Haemost. 2005;3:1976–84.PubMedView ArticleGoogle Scholar
  116. Sedding DG, Braun-Dullaeus RC. Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med. 2006;16:50–5.PubMedView ArticleGoogle Scholar
  117. Gosens R, Stelmack GL, Bos ST, Dueck G, Mutawe MM, Schaafsma D, et al. Caveolin-1 is required for contractile phenotype expression by airway smooth muscle cells. J Cell Mol Med. 2011;15:2430–42.PubMedPubMed CentralView ArticleGoogle Scholar
  118. Maeng J, Sheverdin V, Shin H, Ha I, Bae SS, Yang-Yen H-F, et al. Up-regulation of Rhoa/rho kinase pathway by translationally controlled tumor protein in vascular smooth muscle cells. Int J Mol Sci. 2014;15:10365–76.PubMedPubMed CentralView ArticleGoogle Scholar
  119. Shimokawa H, Sunamura S, Satoh K. RhoA/rho-Kinase in the cardiovascular system. Circ Res. 2016;118:352–66.PubMedView ArticleGoogle Scholar
  120. Vrhovski B, McKay K, Schevzov G, Gunning PW, Weinberger RP. Smooth muscle-specific alpha tropomyosin is a marker of fully differentiated smooth muscle in lung. J Histochem Cytochem. 2005;53:875–83.PubMedView ArticleGoogle Scholar
  121. Thyberg J. Caveolin-1 and caveolae act as regulators of mitogenic signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:1481–3.PubMedView ArticleGoogle Scholar
  122. Peterson TE, Guicciardi ME, Gulati R, Kleppe LS, Mueske CS, Mookadam M, et al. Caveolin-1 can regulate vascular smooth muscle cell fate by switching platelet-derived growth factor signaling from a proliferative to an apoptotic pathway. Arterioscler Thromb Vasc Biol. 2003;23:1521–7.PubMedView ArticleGoogle Scholar
  123. Sathish V, Yang B, Meuchel LW, VanOosten SK, Ryu AJ, Thompson MA, et al. Caveolin-1 and force regulation in porcine airway smooth muscle. Am. J. Physiol. Lung cell. Mol. Phys Ther. 2011;300:L920–9.Google Scholar
  124. Je H-D, Gallant C, Leavis PC, Morgan KG. Caveolin-1 regulates contractility in differentiated vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2004;286:H91–8.PubMedView ArticleGoogle Scholar
  125. Grayson TH, Ohms SJ, Brackenbury TD, Meaney KR, Peng K, Pittelkow YE, et al. Vascular microarray profiling in two models of hypertension identifies caveolin-1, Rgs2 and Rgs5 as antihypertensive targets. BMC Genomics. 2007;8:404.PubMedPubMed CentralView ArticleGoogle Scholar
  126. Gunning P, O’Neill G, Hardeman E. Tropomyosin-based regulation of the actin cytoskeleton in time and space. Physiol Rev. 2008;88:1–35.PubMedView ArticleGoogle Scholar
  127. Marston S, El-Mezgueldi M. Role of tropomyosin in the regulation of contraction in smooth muscle. Adv Exp Med Biol. 2008;644:110–23.PubMedView ArticleGoogle Scholar
  128. Urata Y, Goto S, Kawakatsu M, Yodoi J, Eto M, Akishita M, et al. DHEA attenuates PDGF-induced phenotypic proliferation of vascular smooth muscle A7r5 cells through redox regulation. Biochem Biophys Res Commun. 2010;396:489–94.PubMedView ArticleGoogle Scholar
  129. Bansal G, Das D, Hsieh C-Y, Wang Y-H, Gilmore BA, Wong C-M, et al. IL-22 activates oxidant signaling in pulmonary vascular smooth muscle cells. Cell Signal. 2013;25:2727–33.PubMedView ArticleGoogle Scholar
  130. Fernandes AP, Capitanio A, Selenius M, Brodin O, Rundlöf A-K, Björnstedt M. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology. 2009;55:313–20.PubMedView ArticleGoogle Scholar
  131. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb. 2009;16:532–8.PubMedView ArticleGoogle Scholar
  132. Mieyal JJ, Gallogly MM, Qanungo S, Sabens EA, Shelton MD. Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal. 2008;10:1941–88.PubMedPubMed CentralView ArticleGoogle Scholar
  133. Chandrasekar B, Mummidi S, Perla RP, Bysani S, Dulin NO, Liu F, et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J. 2003;373:547–58.PubMedPubMed CentralView ArticleGoogle Scholar
  134. White GE, Tan TCC, John AE, Whatling C, McPheat WL, Greaves DR. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res. 2010;85:825–35.PubMedView ArticleGoogle Scholar
  135. van der Vorst EPC, Vanags LZ, Dunn LL, Prosser HC, Rye K-A, Bursill CA. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. FASEB J. 2013;27:1413–25.PubMedView ArticleGoogle Scholar
  136. Perros F, Dorfmüller P, Souza R, Durand-Gasselin I, Godot V, Capel F, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J. 2007;29:937–43.PubMedView ArticleGoogle Scholar
  137. Liu W, Jiang L, Bian C, Liang Y, Xing R, Yishakea M, et al. Role of CX3CL1 in diseases. Arch Immunol Ther Exp. 2016;64:371–83.View ArticleGoogle Scholar
  138. Porreca E, Di Febbo C, Reale M, Castellani ML, Baccante G, Barbacane R, et al. Monocyte Chemotactic protein 1 (MCP-1) is a Mitogen for cultured rat vascular smooth muscle cells. J Vasc Res Karger Publishers. 1997;34:58–65.View ArticleGoogle Scholar
  139. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kübler W, et al. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol. 2002;22:914–20.PubMedView ArticleGoogle Scholar
  140. Kundumani-Sridharan V, Singh NK, Kumar S, Gadepalli R, Rao GN. Nuclear factor of activated T cells c1 mediates p21-activated kinase 1 activation in the modulation of chemokine-induced human aortic smooth muscle cell F-actin stress fiber formation, migration, and proliferation and injury-induced vascular wall remodeli. J Biol Chem. 2013;288:22150–62.PubMedPubMed CentralView ArticleGoogle Scholar
  141. Girona J, Rosales R, Plana N, Saavedra P, Masana L, Vallvé J-C. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One. 2013;8:e81914.PubMedPubMed CentralView ArticleGoogle Scholar
  142. Yang Y-J, Wu L-S, Shu B, Qian M-Z. MCPIP1 mediates MCP-1-induced vascular smooth muscle cell proliferation. Acta Phys Sin. 2013;65:616–22.Google Scholar
  143. Qi X, Zhang Y, Li J, Hou D, Xiang Y. Effect of PGC-1α on proliferation, migration, and transdifferentiation of rat vascular smooth muscle cells induced by high glucose. J Biomed Biotechnol. 2012;2012:756426.PubMedPubMed CentralGoogle Scholar
  144. Bhardwaj S, Roy H, Babu M, Shibuya M, Yla-Herttuala S. Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis. 2011;219:84–91.PubMedView ArticleGoogle Scholar
  145. Ikeda U, Okada K, Ishikawa S, Saito T, Kasahara T, Shimada K. Monocyte chemoattractant protein 1 inhibits growth of rat vascular smooth muscle cells. Am J Phys. 1995;268:H1021–6.Google Scholar
  146. Detmar M, Tenorio S, Hettmannsperger U, Ruszczak Z, Orfanos CE. Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol. 1992;98:147–53.PubMedView ArticleGoogle Scholar
  147. Braun M. Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc Res. 1999;41:395–401.PubMedView ArticleGoogle Scholar
  148. Lawson C, Ainsworth ME, McCormack AM, Yacoub M, Rose ML. Effects of cross-linking ICAM-1 on the surface of human vascular smooth muscle cells: induction of VCAM-1 but no proliferation. Cardiovasc Res. 2001;50:547–55.PubMedView ArticleGoogle Scholar
  149. Jones FS, Meech R, Edelman DB, Oakey RJ, Jones PL. Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. Circ Res. 2001;89:131–8.PubMedView ArticleGoogle Scholar
  150. Jones FS, McKean DM, Meech R, Edelman DB, Oakey RJ, Jones PL. Regulation of vascular smooth muscle cell growth and adhesion by paired-related homeobox genes. Chest. 2002;121:89S–90S.PubMedView ArticleGoogle Scholar
  151. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS, Berk BC, et al. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314–25.PubMedView ArticleGoogle Scholar
  152. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 1996;16:673–7.PubMedView ArticleGoogle Scholar
  153. Bishop-Bailey D, Burke-Gaffney A, Hellewell PG, Pepper JR, Mitchell JA. Cyclo-oxygenase-2 regulates inducible ICAM-1 and VCAM-1 expression in human vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;249:44–7.PubMedView ArticleGoogle Scholar
  154. Couffinhal T, Duplaa C, Moreau C, Lamaziere JM, Bonnet J. Regulation of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 in human vascular smooth muscle cells. Circ Res. 1994;74:225–34.PubMedView ArticleGoogle Scholar
  155. Couffinhal T, Duplàa C, Labat L, Lamaziere JM, Moreau C, Printseva O, et al. Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells. Arterioscler Thromb. 1993;13:407–14.PubMedView ArticleGoogle Scholar
  156. Yao Q-P, Zhang P, Qi Y-X, Chen S-G, Shen B, Han Y, et al. The role of SIRT6 in the differentiation of vascular smooth muscle cells in response to cyclic strain. Int J Biochem Cell Biol. 2014;49:98–104.PubMedView ArticleGoogle Scholar
  157. Shang Y, Yoshida T, Amendt BA, Martin JF, Owens GK. Pitx2 is functionally important in the early stages of vascular smooth muscle cell differentiation. J Cell Biol. 2008;181:461–73.PubMedPubMed CentralView ArticleGoogle Scholar
  158. Hautmann MB, Thompson MM, Swartz EA, Olson EN, Owens GK. Angiotensin II-induced stimulation of smooth muscle alpha-actin expression by serum response factor and the homeodomain transcription factor MHox. Circ Res. 1997;81:600–10.PubMedView ArticleGoogle Scholar
  159. Yoshida T, Hoofnagle MH, Owens GK. Myocardin and Prx1 contribute to angiotensin II-induced expression of smooth muscle alpha-actin. Circ Res. 2004;94:1075–82.PubMedView ArticleGoogle Scholar
  160. Liao Y, Shikapwashya ON, Shteyer E, Dieckgraefe BK, Hruz PW, Rudnick DA. Delayed hepatocellular mitotic progression and impaired liver regeneration in early growth response-1-deficient mice. J Biol Chem. 2004;279:43107–16.PubMedView ArticleGoogle Scholar
  161. Kharbanda S, Nakamura T, Stone R, Hass R, Bernstein S, Datta R, et al. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest. 1991;88:571–7.PubMedPubMed CentralView ArticleGoogle Scholar
  162. Tan CM, Limbird LE. The alpha2-adrenergic receptors - lessons from knockouts. In: Perez DM, editor. Adren. Recept. 21st century. Totowa: Humana Press; 2006. p. 241–65.View ArticleGoogle Scholar
  163. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB. Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J Biol Chem. 1992;267:15795–801.PubMedGoogle Scholar
  164. Kimura TE, Duggirala A, Smith MC, White S, Sala-Newby GB, Newby AC, et al. The hippo pathway mediates inhibition of vascular smooth muscle cell proliferation by cAMP. J Mol Cell Cardiol. 2016;90:1–10.PubMedPubMed CentralView ArticleGoogle Scholar
  165. Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68–75.PubMedView ArticleGoogle Scholar
  166. Hunter T. Protein kinases and phosphatases: the yin and Yang of protein phosphorylation and signaling. Cell. 1995;80:225–36.PubMedView ArticleGoogle Scholar
  167. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912–34.PubMedView ArticleGoogle Scholar
  168. Muir D, Varon S, Manthorpe M. An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures. Anal Biochem. 1990;185:377–82.PubMedView ArticleGoogle Scholar
  169. Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ, Minor L. Cell Viability Assays. 2013 May 1 [Updated 2016 Jul 1]. In: Sittampalam GS, Coussens NP, Brimacombe K, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK144065/.
  170. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105.PubMedPubMed CentralView ArticleGoogle Scholar
  171. Feala JD, Cortes J, Duxbury PM, McCulloch AD, Piermarocchi C, Paternostro G. Statistical properties and robustness of biological controller-target networks. PLoS One. 2012;7:e29374.PubMedPubMed CentralView ArticleGoogle Scholar
  172. Tran TP, Ong E, Hodges AP, Paternostro G, Piermarocchi C. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression. BMC Syst Biol. 2014;8:74.PubMedPubMed CentralView ArticleGoogle Scholar
  173. Lipskaia L, Pourci M-L, Deloménie C, Combettes L, Goudounèche D, Paul J-L, et al. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res. 2003;92:1115–22.PubMedView ArticleGoogle Scholar
  174. Kudryavtseva O, Aalkjaer C, Matchkov VV. Vascular smooth muscle cell phenotype is defined by Ca2+−dependent transcription factors. FEBS J. 2013;280:5488–99.PubMedView ArticleGoogle Scholar
  175. Li S, Sun N. Regulation of intracellular Ca2+ and calcineurin by NO/PKG in proliferation of vascular smooth muscle cells. Acta Pharmacol Sin. 2005;26:323–8.PubMedView ArticleGoogle Scholar
  176. Dumler I, Stepanova V, Jerke U, Mayboroda OA, Vogel F, Bouvet P, et al. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin. Curr Biol. 1999;9:1468–76.PubMedView ArticleGoogle Scholar
  177. Davis R, Pillai S, Lawrence N, Sebti S, Chellappan SP. TNF-α-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes. Cell Cycle. 2012;11:109–18.PubMedPubMed CentralView ArticleGoogle Scholar
  178. Li L, Zhou Y, Wang C, Zhao Y-L, Zhang Z-G, Fan D, et al. Src tyrosine kinase regulates angiotensin II-induced protein kinase Czeta activation and proliferation in vascular smooth muscle cells. Peptides. 2010;31:1159–64.PubMedView ArticleGoogle Scholar
  179. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem. 2009;284:11953–62.PubMedPubMed CentralView ArticleGoogle Scholar
  180. Walcher D, Babiak C, Poletek P, Rosenkranz S, Bach H, Betz S, et al. C-peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res. 2006;99:1181–7.PubMedView ArticleGoogle Scholar
  181. Jeremy J. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res. 1999;43:580–94.PubMedView ArticleGoogle Scholar
  182. Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, et al. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling. Circ Res. 1999;85:12–22.PubMedView ArticleGoogle Scholar
  183. Yang P-S, Wang M-J, Jayakumar T, Chou D-S, Ko C-Y, Hsu M-J, et al. Antiproliferative activity of Hinokitiol, a Tropolone derivative, is mediated via the inductions of p-JNK and p-PLCγ1 signaling in PDGF-BB-stimulated vascular smooth muscle cells. Molecules. 2015;20:8198–212.PubMedView ArticleGoogle Scholar
  184. Nagayama K, Kyotani Y, Zhao J, Ito S, Ozawa K, Bolstad FA, et al. Exendin-4 prevents vascular smooth muscle cell proliferation and migration by Angiotensin II via the inhibition of ERK1/2 and JNK signaling pathways. PLoS One. 2015;10:e0137960.PubMedPubMed CentralView ArticleGoogle Scholar
  185. Yu L, Huang X, Huang K, Gui C, Huang Q, Wei B. Ligustrazine attenuates the platelet-derived growth factor-BB-induced proliferation and migration of vascular smooth muscle cells by interrupting extracellular signal-regulated kinase and P38 mitogen-activated protein kinase pathways. Mol Med Rep. 2015;12:705–11.PubMedGoogle Scholar
  186. Chen Z, Cai Y, Zhang W, Liu X, Liu S. Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med. 2014;8:1253–8.PubMedPubMed CentralGoogle Scholar
  187. Shen Y-J, Zhu X-X, Yang X, Jin B, Lu J-J, Ding B, et al. Cardamonin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by downregulating p38 MAPK, Akt, and ERK phosphorylation. J Nat Med. 2014;68:623–9.PubMedView ArticleGoogle Scholar
  188. Zhang Y, Jiang Z, Li L, Zhou Y, Song Z, Shu M. Geminin interference facilitates vascular smooth muscle cell proliferation by upregulation of CDK-1. Cardiovasc Drugs Ther. 2014;28:407–14.PubMedView ArticleGoogle Scholar
  189. Schad JF, Meltzer KR, Hicks MR, Beutler DS, Cao TV, Standley PR. Cyclic strain upregulates VEGF and attenuates proliferation of vascular smooth muscle cells. Vasc Cell. 2011;3:21.PubMedPubMed CentralView ArticleGoogle Scholar
  190. Terano T, Tanaka T, Tamura Y, Kitagawa M, Higashi H, Saito Y, et al. Eicosapentaenoic acid and docosahexaenoic acid inhibit vascular smooth muscle cell proliferation by inhibiting phosphorylation of Cdk2-cyclinE comp... - PubMed - NCBI. Biochem Biophys Res Commun. 1999;254:502–6.PubMedView ArticleGoogle Scholar
  191. Zhang X, Liu L, Chen C, Chi Y-L, Yang X-Q, Xu Y, et al. Interferon regulatory factor-1 together with reactive oxygen species promotes the acceleration of cell cycle progression by up-regulating the cyclin E and CDK2 genes during high glucose-induced proliferation of vascular smooth muscle cells. Cardiovasc Diabetol. 2013;12:147.PubMedPubMed CentralView ArticleGoogle Scholar
  192. Kristof AS, Pacheco-Rodriguez G, Schremmer B, Moss J. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther. 2005;314:1134–43.PubMedView ArticleGoogle Scholar
  193. Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA, et al. PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Phys Lung Cell Mol Phys. 2002;283:L354–63.Google Scholar
  194. Silfani TN, Freeman EJ. Phosphatidylinositide 3-kinase regulates angiotensin II-induced cytosolic phospholipase A2 activity and growth in vascular smooth muscle cells. Arch Biochem Biophys. 2002;402:84–93.PubMedView ArticleGoogle Scholar
  195. Saward L, Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res. 1997;81:249–57.PubMedView ArticleGoogle Scholar
  196. Freeman EJ, Sheakley ML, Clements RJ. Angiotensin II-dependent growth of vascular smooth muscle cells requires transactivation of the epidermal growth factor receptor via a cytosolic phospholipase a(2)-mediated release of arachidonic acid. Arch Biochem Biophys. 2010;498:50–6.PubMedView ArticleGoogle Scholar
  197. Rodríguez-Moyano M, Díaz I, Dionisio N, Zhang X, Avila-Medina J, Calderón-Sánchez E, et al. Urotensin-II promotes vascular smooth muscle cell proliferation through store-operated calcium entry and EGFR transactivation. Cardiovasc Res. 2013;100:297–306.PubMedPubMed CentralView ArticleGoogle Scholar
  198. Robinson JD, Pitcher JA. G protein-coupled receptor kinase 2 (GRK2) is a rho-activated scaffold protein for the ERK MAP kinase cascade. Cell Signal. 2013;25:2831–9.PubMedView ArticleGoogle Scholar
  199. Savikko J, Rintala JM, Rintala S, Koskinen P. Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte-macrophage function in vitro. Transpl Immunol. 2015;32:175–8.PubMedView ArticleGoogle Scholar
  200. Watanabe T, Pakala R, Katagiri T, Benedict CR. Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation. Atherosclerosis. 2001;159:269–79.PubMedView ArticleGoogle Scholar
  201. Peppelenbosch MP. Kinome profiling. Science. 2012;2012:306798.Google Scholar
  202. Schutkowski M, Reineke U, Reimer U. Peptide arrays for Kinase profiling. Chembiochem. WILEY-VCH Verlag. 2005;6:513–21.PubMedView ArticleGoogle Scholar
  203. Shigaki S, Yamaji T, Han X, Yamanouchi G, Sonoda T, Okitsu O, et al. A peptide microarray for the detection of protein kinase activity in cell lysate. Anal Sci. 2007;23:271–5.PubMedView ArticleGoogle Scholar
  204. Ikebe M, Hartshorne DJ. Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase. J Biol Chem. 1985;260:10027–31.PubMedGoogle Scholar
  205. Ikebe M, Hartshorne DJ, Elzinga M. Identification, phosphorylation, and dephosphorylation of a second site for myosin light chain kinase on the 20,000-dalton light chain of smooth muscle myosin. J Biol Chem. 1986;261:36–9.PubMedGoogle Scholar
  206. Niiro N, Ikebe M. Zipper-interacting protein kinase induces ca(2+)-free smooth muscle contraction via myosin light chain phosphorylation. J Biol Chem. 2001;276:29567–74.PubMedView ArticleGoogle Scholar
  207. Moffat LD, Brown SBA, Grassie ME, Ulke-Lemée A, Williamson LM, Walsh MP, et al. Chemical genetics of zipper-interacting protein kinase reveal myosin light chain as a bona fide substrate in permeabilized arterial smooth muscle. J Biol Chem. 2011;286:36978–91.PubMedPubMed CentralView ArticleGoogle Scholar
  208. Deng JT, Van Lierop JE, Sutherland C, Walsh MP. Ca2+−independent smooth muscle contraction. A novel function for integrin-linked kinase. J Biol Chem. 2001;276:16365–73.PubMedView ArticleGoogle Scholar
  209. Wilson DP, Sutherland C, Borman MA, Deng JT, Macdonald JA, Walsh MP. Integrin-linked kinase is responsible for Ca2+−independent myosin diphosphorylation and contraction of vascular smooth muscle. Biochem J. 2005;392:641–8.PubMedPubMed CentralView ArticleGoogle Scholar
  210. Sutherland C, Walsh MP. Myosin regulatory light chain diphosphorylation slows relaxation of arterial smooth muscle. J Biol Chem. 2012;287:24064–76.PubMedPubMed CentralView ArticleGoogle Scholar
  211. Hunter T. Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol. 2009;21:140–6.PubMedPubMed CentralView ArticleGoogle Scholar
  212. Hunter T. The Croonian lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos Trans R Soc Lond Ser B Biol Sci. 1998;353:583–605.View ArticleGoogle Scholar
  213. Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell. 2007;128:225–31.PubMedView ArticleGoogle Scholar
  214. Kim HK, Kim JW, Zilberstein A, Margolis B, Kim JG, Schlessinger J, et al. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell. 1991;65:435–41.PubMedView ArticleGoogle Scholar
  215. Sekiya F, Poulin B, Kim YJ, Rhee SG. Mechanism of tyrosine Phosphorylation and activation of Phospholipase C- 1: TYROSINE 783 PHOSPHORYLATION IS NOT SUFFICIENT FOR LIPASE ACTIVATION. J Biol Chem. 2004;279:32181–90.PubMedView ArticleGoogle Scholar
  216. Marrero MB, Venema RC, Ma H, Ling BN, Eaton DC. Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int. 1998;53:1259–68.PubMedView ArticleGoogle Scholar
  217. Boudot C, Petitfrère E, Kadri Z, Chretien S, Mayeux P, Haye B, et al. Erythropoietin induces glycosylphosphatidylinositol hydrolysis. Possible involvement of phospholipase c-gamma(2). J Biol Chem. 1999;274:33966–72.PubMedView ArticleGoogle Scholar
  218. Balagopalan L, Coussens NP, Sherman E, Samelson LE, Sommers CL. The LAT story: a tale of Cooperativity, coordination, and choreography. Cold Spring Harb Perspect Biol Cold Spring Harbor Lab. 2010;2:a005512.Google Scholar
  219. Law CL, Chandran KA, Sidorenko SP, Clark EA. Phospholipase C-gamma1 interacts with conserved phosphotyrosyl residues in the linker region of Syk and is a substrate for Syk. Mol Cell Biol. 1996;16:1305–15.PubMedPubMed CentralView ArticleGoogle Scholar
  220. Kurosaki T, Maeda A, Ishiai M, Hashimoto A, Inabe K, Takata M. Regulation of the phospholipase C-gamma2 pathway in B cells. Immunol Rev. 2000;176:19–29.PubMedView ArticleGoogle Scholar
  221. Cotecchia S, Kobilka BK, Daniel KW, Nolan RD, Lapetina EY, Caron MG, et al. Multiple second messenger pathways of alpha-adrenergic receptor subtypes expressed in eukaryotic cells. J Biol Chem. 1990;265:63–9.PubMedGoogle Scholar
  222. Annerén C, Lindholm CK, Kriz V, Welsh M. The FRK/RAK-SHB signaling cascade: a versatile signal-transduction pathway that regulates cell survival, differentiation and proliferation. Curr Mol Med. 2003;3:313–24.PubMedView ArticleGoogle Scholar
  223. Li F, Jiang Y, Zheng Q, Yang X, Wang S. TEC protein tyrosine kinase is involved in the Erk signaling pathway induced by HGF. Biochem Biophys Res Commun. 2011;404:79–85.PubMedView ArticleGoogle Scholar
  224. Wang S-Y, Li F-F, Zheng H, Yu K-K, Ni F, Yang X-M, et al. Rapid induction and activation of Tec tyrosine kinase in liver regeneration. J Gastroenterol Hepatol. 2006;21:668–73.PubMedView ArticleGoogle Scholar
  225. Biswas P, Canosa S, Schoenfeld J, Schoenfeld D, Tucker A, Madri JA. PECAM-1 promotes beta-catenin accumulation and stimulates endothelial cell proliferation. Biochem Biophys Res Commun. 2003;303:212–8.PubMedView ArticleGoogle Scholar
  226. Nickoloff BJ, Muller WA, Ratti CM, McDonnell SL CZ, Newman PJ, Berndt MC, Gorsky J, White GC, Paddock LS MW, Stockinger H, Gadd SJ, Eher R et al, Nickoloff BJ GC, BJ N, et al. PECAM-1 (CD31) is expressed on proliferating endothelial cells, Stromal spindle-shaped cells, and dermal Dendrocytes in Kaposi’s sarcoma. Arch Dermatol. American Medical Association; 1993;129:250.Google Scholar
  227. Tanyong DI, Panichob P, Kheansaard W, Fucharoen S. Effect of tumor necrosis factor-alpha on erythropoietin and erythropoietin receptor-induced Erythroid progenitor cell proliferation in β-Thalassemia/hemoglobin E patients. Turkish J. Haematol Off J Turkish Soc Haematol. 2015;32:304–10.View ArticleGoogle Scholar
  228. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, et al. Erythropoietin stimulates proliferation and interferes with differentiation of Myoblasts. J Biol Chem. 2000;275:39754–61.PubMedView ArticleGoogle Scholar
  229. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2008;27:1095–105.PubMedView ArticleGoogle Scholar
  230. Mitra S, Beach C, Feng G-S, Plattner R. SHP-2 is a novel target of Abl kinases during cell proliferation. J Cell Sci. 2008;121:3335–46.PubMedPubMed CentralView ArticleGoogle Scholar
  231. Pan S, An P, Zhang R, He X, Yin G, Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002;22:7512–23.PubMedPubMed CentralView ArticleGoogle Scholar
  232. Abassi YA, Rehn M, Ekman N, Alitalo K, Vuori K. p130Cas couples the tyrosine kinase Bmx/Etk with regulation of the actin cytoskeleton and cell migration. J Biol Chem. 2003;278:35636–43.PubMedView ArticleGoogle Scholar
  233. Liu B, Barbosa-Sampaio H, Jones PM, Persaud SJ, Muller DS. The CaMK4/CREB/IRS-2 cascade stimulates proliferation and inhibits apoptosis of β-cells. PLoS One. 2012;7:e45711.PubMedPubMed CentralView ArticleGoogle Scholar
  234. Ichinose K, Rauen T, Juang Y-T, Kis-Toth K, Mizui M, Koga T, et al. Cutting edge: calcium/Calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J Immunol. 2011;187:5500–4.PubMedPubMed CentralView ArticleGoogle Scholar
  235. Whitworth H, Bhadel S, Ivey M, Conaway M, Spencer A, Hernan R, et al. Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. PLoS One. 2012;7:e38950.PubMedPubMed CentralView ArticleGoogle Scholar
  236. Yang F, Cao H, Xiao Q, Guo X, Zhuang Y, Zhang C, et al. Transcriptome analysis and Gene identification in the pulmonary artery of broilers with Ascites syndrome. PLoS One. 2016;11:e0156045.PubMedPubMed CentralView ArticleGoogle Scholar
  237. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739–43.PubMedPubMed CentralView ArticleGoogle Scholar
  238. Olson NE, Chao S, Lindner V, Reidy MA. Intimal smooth muscle cell proliferation after balloon catheter injury. The role of basic fibroblast growth factor. Am. J. Pathologica. 1992;140:1017–23.Google Scholar
  239. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507–11.PubMedPubMed CentralView ArticleGoogle Scholar
  240. Grotendorst GR, Chang T, Seppä HE, Kleinman HK, Martin GR. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol. 1982;113:261–6.PubMedView ArticleGoogle Scholar
  241. Satoh C, Fukuda N, Hu WY, Nakayama M, Kishioka H, Kanmatsuse K. Role of endogenous angiotensin II in the increased expression of growth factors in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2001;37:108–18.PubMedView ArticleGoogle Scholar
  242. Ali S, Becker MW, Davis MG, Dorn GW. Dissociation of vasoconstrictor-stimulated basic fibroblast growth factor expression from hypertrophic growth in cultured vascular smooth muscle cells. Relevant roles of protein kinase C. Circ Res. 1994;75:836–43.PubMedView ArticleGoogle Scholar
  243. New DC, Wong YH. Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal. 2007;2:2.PubMedPubMed CentralView ArticleGoogle Scholar
  244. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011;10:47–60.PubMedView ArticleGoogle Scholar
  245. Li B, Du T, Li H, Gu L, Zhang H, Huang J, et al. Signalling pathways for transactivation by dexmedetomidine of epidermal growth factor receptors in astrocytes and its paracrine effect on neurons. Br J Pharmacol. 2008;154:191–203.PubMedPubMed CentralView ArticleGoogle Scholar
  246. Harun-Or-Rashid M, Díaz-DelCastillo M, Galindo-Romero C, Hallböök F. Alpha2-adrenergic-agonist Brimonidine stimulates negative feedback and attenuates injury-induced Phospho-ERK and dedifferentiation of chicken Müller cells. Invest Ophthalmol Vis Sci. 2015;56:5933–45.PubMedView ArticleGoogle Scholar
  247. Zwick E, Hackel PO, Prenzel N, Ullrich A. The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol Sci. 1999;20:408–12.PubMedView ArticleGoogle Scholar
  248. Marshall C. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell Cell Press. 1995;80:179–85.Google Scholar
  249. Yang X, Zhu MJ, Sreejayan N, Ren J, Du M. Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Mol Cell. 2005;20:263–70.View ArticleGoogle Scholar
  250. Li Y, Lévesque L-O, Anand-Srivastava MB. Epidermal growth factor receptor transactivation by endogenous vasoactive peptides contributes to hyperproliferation of vascular smooth muscle cells of SHR. Am J Physiol Heart Circ Physiol. 2010;299:H1959–67.PubMedView ArticleGoogle Scholar
  251. Zarnegar R. Regulation of HGF and HGFR gene expression. EXS. 1995;74:33–49.PubMedGoogle Scholar
  252. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol Nature Publishing Group. 2003;4:915–25.PubMedView ArticleGoogle Scholar
  253. Salgia R. Role of c-met in cancer: emphasis on lung cancer. Semin Oncol NIH Public Access. 2009;36:S52–8.PubMedPubMed CentralView ArticleGoogle Scholar
  254. You W-K, McDonald DM. The hepatocyte growth factor/c-met signaling pathway as a therapeutic target to inhibit angiogenesis. BMB Rep. 2008;41:833–9.PubMedPubMed CentralView ArticleGoogle Scholar
  255. Fischer OM, Giordano S, Comoglio PM, Ullrich A. Reactive oxygen species mediate met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J Biol Chem. 2004;279:28970–8.PubMedView ArticleGoogle Scholar
  256. Taher TE, Derksen PW, de Boer OJ, Spaargaren M, Teeling P, van der Wal AC, et al. Hepatocyte growth factor triggers signaling cascades mediating vascular smooth muscle cell migration. Biochem Biophys Res Commun. 2002;298:80–6.PubMedView ArticleGoogle Scholar
  257. Ma H, Calderon TM, Kessel T, Ashton AW, Berman JW. Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration. Circ Res. 2003;93:1066–73.PubMedView ArticleGoogle Scholar
  258. Nakatsu MN, Sainson RCA, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, et al. VEGF121 and VEGF165 regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Investig Nature Publishing Group. 2003;83:1873–85.PubMedView ArticleGoogle Scholar
  259. Meyer RD, Rahimi N. Comparative structure-function analysis of VEGFR-1 and VEGFR-2: what have we learned from chimeric systems? Ann N Y Acad Sci. 2003;995:200–7.PubMedView ArticleGoogle Scholar
  260. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456:809–13.PubMedPubMed CentralView ArticleGoogle Scholar
  261. Cardús A, Parisi E, Gallego C, Aldea M, Fernández E, Valdivielso JM, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. Elsevier. 2006;69:1377–84.PubMedView ArticleGoogle Scholar
  262. Parenti A, Brogelli L, Filippi S, Donnini S, Ledda F, Buschmann I, et al. Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res. 2002;55:201–12.PubMedView ArticleGoogle Scholar
  263. Chandra A, Angle N. Vascular endothelial growth factor stimulates a novel calcium-signaling pathway in vascular smooth muscle cells. Surgery. 2005;138:780–7.PubMedView ArticleGoogle Scholar
  264. Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta -adrenoreceptor/cAMP/protein kinase a pathway involving Src but independently of Erk1/2. J Biol Chem. 2000;275:13802–11.PubMedView ArticleGoogle Scholar
  265. Muthig V, Gilsbach R, Haubold M, Philipp M, Ivacevic T, Gessler M, et al. Upregulation of soluble vascular endothelial growth factor receptor 1 contributes to angiogenesis defects in the placenta of 2B-Adrenoceptor deficient mice. Circ Res. 2007;101:682–91.PubMedView ArticleGoogle Scholar
  266. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39:469–78.PubMedGoogle Scholar
  267. Lee MW, Severson DL. Signal transduction in vascular smooth muscle: diacylglycerol second messengers and PKC action. Am J Phys. 1994;267:C659–78.Google Scholar
  268. Khalil RA. Protein Kinase C inhibitors as modulators of vascular function and their application in vascular disease. Pharmaceuticals (Basel). 2013;6:407–39.View ArticleGoogle Scholar
  269. Khalil RA. Chapter 6: protein Kinase C. Regul. Vasc. Smooth muscle Funct. Morgan & Claypool Life Sciences: San Rafael; 2010.Google Scholar
  270. Wang Y, Yan T, Wang Q, Wang W, Xu J, Wu X, et al. PKC-dependent extracellular signal-regulated kinase 1/2 pathway is involved in the inhibition of Ib on AngiotensinII-induced proliferation of vascular smooth muscle cells. Biochem Biophys Res Commun. 2008;375:151–5.PubMedView ArticleGoogle Scholar
  271. Molnar P, Perrault R, Louis S, Zahradka P. The cyclic AMP response element-binding protein (CREB) mediates smooth muscle cell proliferation in response to angiotensin II. J Cell Commun Signal. 2014;8:29–37.PubMedView ArticleGoogle Scholar
  272. Ma J, Feng Y, Li Z, Tang C. The effect of adrenomedullin and proadrenomedullin N-terminal 20 peptide on angiotensin II induced vascular smooth muscle cell proliferation. Iran J Basic Med Sci. 2016;19:49–54.PubMedPubMed CentralGoogle Scholar
  273. Yang J, Han Y, Sun H, Chen C, He D, Guo J, et al. (−)-Epigallocatechin gallate suppresses proliferation of vascular smooth muscle cells induced by high glucose by inhibition of PKC and ERK1/2 signalings. J Agric Food Chem. 2011;59:11483–90.PubMedView ArticleGoogle Scholar
  274. Liou S-F, Yeh J-L, Liang J-C, Chiu C-C, Lin Y-T, Chen I-J. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-a through PKC and ERK 1/2 pathway. J Cardiovasc Pharmacol. 2004;44:539–51.PubMedView ArticleGoogle Scholar
  275. Stäuble B, Boscoboinik D, Azzi A. Purification and kinetic properties of protein kinase C from cultured smooth muscle cells. Biochem Mol Biol Int. 1993;29:203–11.PubMedGoogle Scholar
  276. Chang C-C, Lee J-J, Chiang C-W, Jayakumar T, Hsiao G, Hsieh C-Y, et al. Inhibitory effect of PMC, a potent hydrophilic α-tocopherol derivative, on vascular smooth muscle cell proliferation: the pivotal role of PKC-α translocation. Pharm Biol. 2010;48:938–46.PubMedView ArticleGoogle Scholar
  277. Li L, Gao T, He S, Xu G, Yang L. Effect of heparin-derived oligosaccharide on vascular smooth muscle cell proliferation through inhibition of PKC-alpha expression. Acta Pharm Sin. 2012;47:993–1000.Google Scholar
  278. Liu B, Ryer EJ, Kundi R, Kamiya K, Itoh H, Faries PL, et al. Protein kinase C-delta regulates migration and proliferation of vascular smooth muscle cells through the extracellular signal-regulated kinase 1/2. J Vasc Surg. 2007;45:160–8.PubMedPubMed CentralView ArticleGoogle Scholar
  279. Fukumoto S, Nishizawa Y, Hosoi M, Koyama H, Yamakawa K, Ohno S, et al. Protein Kinase C delta inhibits the proliferation of vascular smooth muscle cells by suppressing G1 Cyclin expression. J Biol Chem. 1997;272:13816–22.PubMedView ArticleGoogle Scholar
  280. Peppel K, Jacobson A, Huang X, Murray JP, Oppermann M, Freedman NJ. Overexpression of G protein-coupled receptor kinase-2 in smooth muscle cells attenuates mitogenic signaling via G protein-coupled and platelet-derived growth factor receptors. Circulation. 2000;102:793–9.PubMedView ArticleGoogle Scholar
  281. Peppel K, Zhang L, Huynh TTT, Huang X, Jacobson A, Brian L, et al. Overexpression of G protein-coupled receptor kinase-2 in smooth muscle cells reduces neointimal hyperplasia. J Mol Cell Cardiol. 2002;34:1399–409.PubMedView ArticleGoogle Scholar
  282. Heck DA, Bylund DB. Mechanism of down-regulation of alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther. 1997;282:1219–27.PubMedGoogle Scholar
  283. Li W, Ai N, Wang S, Bhattacharya N, Vrbanac V, Collins M, et al. GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proc Natl Acad Sci U S A. 2014;111:1521–6.PubMedPubMed CentralView ArticleGoogle Scholar
  284. Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, et al. GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget. 2016;7:45171–85.PubMedPubMed CentralGoogle Scholar
  285. Sayeski PP, Ali MS. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Exp Cell Res. 2003;287:339–49.PubMedView ArticleGoogle Scholar
  286. Yao H-L, Gao F-H, Li Z-Z, Wu H-X, Xu M-D, Zhang Z, et al. Monocyte chemoattractant protein-1 mediates angiotensin II-induced vascular smooth muscle cell proliferation via SAPK/JNK and ERK1/2. Mol Cell Biochem. 2012;366:355–62.PubMedView ArticleGoogle Scholar
  287. Velculescu VE. Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes--SAGE and its use in global gene expression analysis. Science. 1999;286:1491–2.PubMedView ArticleGoogle Scholar
  288. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, et al. Analysis of human transcriptomes. Nat Genet. 1999;23:387–8.PubMedView ArticleGoogle Scholar
  289. Li T, Liu X, Liu D, Wang Z. Sensitive detection of protein kinase a activity in cell lysates by peptide microarray-based assay. Anal Chem. 2013;85:7033–7.PubMedView ArticleGoogle Scholar
  290. Grötzinger C. Peptide microarrays for medical applications in autoimmunity, infection, and cancer. Methods Mol Biol. 2016;1352:213–21.PubMedView ArticleGoogle Scholar
  291. Lin E, Sikand A, Wickware J, Hao Y, Derda R. Peptide microarray patterning for controlling and monitoring cell growth. Acta Biomater. 2016;34:53–9.PubMedView ArticleGoogle Scholar
  292. Diks SH, Richel DJ, Peppelenbosch MP. LPS signal transduction: the picture is becoming more complex. Curr Top Med Chem. 2004;4:1115–26.PubMedView ArticleGoogle Scholar
  293. Diks SH, van Deventer SJ, Peppelenbosch MP. Lipopolysaccharide recognition, internalisation, signalling and other cellular effects. J Endotoxin Res. 2001;7:335–48.PubMedGoogle Scholar
  294. Shokat K, Velleca M. Novel chemical genetic approaches to the discovery of signal transduction inhibitors. Drug Discov Today. 2002;7:872–9.PubMedView ArticleGoogle Scholar
  295. Peppelenbosch MP, Frijns N, Fuhler G. Systems medicine approaches for peptide array-based protein kinase profiling: progress and prospects. Expert Rev Proteomics. 2016;13:571–8.PubMedView ArticleGoogle Scholar
  296. Yamamoto T, Mori T, Katayama Y. Microarray Technologies for Intracellular Kinome Analysis. Curr Med Chem Bentham Science Publishers. 2014;21:2542–52.PubMedView ArticleGoogle Scholar
  297. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995;9:576–96.PubMedGoogle Scholar
  298. Dumler I, Weis A, Mayboroda OA, Maasch C, Jerke U, Haller H, et al. The Jak/stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998;273:315–21.PubMedView ArticleGoogle Scholar
  299. Hollenbeck ST, Itoh H, Louie O, Faries PL, Liu B, Kent KC. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the α2β1 integrin and PDGFβ receptor. Biochem Biophys Res Commun. 2004;325:328–37.PubMedView ArticleGoogle Scholar
  300. Pertel T, Zhu D, Panettieri RA, Yamaguchi N, Emala CW, Hirshman CA. Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells. AJP Lung Cell Mol Physiol. 2005;290:L492–500.View ArticleGoogle Scholar
  301. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene. 2004;23:7969–78.PubMedView ArticleGoogle Scholar
  302. Ingley E. Functions of the Lyn tyrosine kinase in health and disease. Cell Commun Signal. 2012;10:21.PubMedPubMed CentralView ArticleGoogle Scholar
  303. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002;12:226–30.PubMedView ArticleGoogle Scholar
  304. Guerra B, Issinger OG. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis. 1999;20:391–408.PubMedView ArticleGoogle Scholar
  305. Pinna LA, Meggio F. Protein kinase CK2 (&quot;casein kinase-2&quot;) and its implication in cell division and proliferation. Prog Cell Cycle Res. 1997;3:77–97.PubMedView ArticleGoogle Scholar
  306. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008;7:3664–8.PubMedView ArticleGoogle Scholar
  307. Wang L, Gao W, Hu F, Xu Z, Wang F. MicroRNA-874 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting CDK9. FEBS Lett. 2014;588:4527–35.PubMedView ArticleGoogle Scholar
  308. Kawabe J, Okumura S, Lee M-C, Sadoshima J, Ishikawa Y. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2004;286:H1845–52.PubMedView ArticleGoogle Scholar
  309. Chang Y, Ceacareanu B, Zhuang D, Zhang C, Pu Q, Ceacareanu AC, et al. Counter-regulatory function of protein tyrosine phosphatase 1B in platelet-derived growth factor- or fibroblast growth factor-induced motility and proliferation of cultured smooth muscle cells and in neointima formation. Arterioscler Thromb Vasc Biol. 2006;26:501–7.PubMedView ArticleGoogle Scholar
  310. Kandadi MR, Stratton MS, Ren J. The role of Src homology 2 containing protein tyrosine phosphatase 2 in vascular smooth muscle cell migration and proliferation. Acta Pharmacol Sin. 2010;31:1277–83.PubMedPubMed CentralView ArticleGoogle Scholar
  311. Chang Y, Zhuang D, Zhang C, Hassid A. Increase of PTP levels in vascular injury and in cultured aortic smooth muscle cells treated with specific growth factors. Am J Physiol Heart Circ Physiol. 2004;287:H2201–8.PubMedView ArticleGoogle Scholar
  312. Buchet R, Millán JL, Magne D. Multisystemic functions of alkaline phosphatases. Methods Mol Biol. 2013;1053:27–51.PubMedView ArticleGoogle Scholar
  313. Liu G, Deng J, Zhang Q, Song W, Chen S, Lou X, et al. Porphyromonas Gingivalis Lipopolysaccharides stimulation of vascular smooth muscle cells activates proliferation and calcification. J Periodontol. 2016;87:828–36.PubMedView ArticleGoogle Scholar
  314. Satterthwaite AB, Li Z, Witte ON. Btk function in B cell development and response. Semin Immunol. 1998;10:309–16.PubMedView ArticleGoogle Scholar
  315. Sur S, Swier VJ, Radwan MM, Agrawal DK. Increased expression of Phosphorylated polo-like Kinase 1 and Histone in bypass vein graft and coronary arteries following angioplasty. PLoS One. 2016;11:e0147937.PubMedPubMed CentralView ArticleGoogle Scholar
  316. Wang X, Chen L, Liu J, Yan T, Wu G, Xia Y, et al. In vivo treatment of rat arterial adventitia with interleukin-1β induces intimal proliferation via the JAK2/STAT3 signaling pathway. Mol Med Rep. 2016;13:3451–8.PubMedPubMed CentralGoogle Scholar
  317. Zhao J, Zhang M, Li W, Su X, Zhu L, Hang C. Suppression of JAK2/STAT3 signaling reduces end-to-end arterial anastomosis induced cell proliferation in common carotid arteries of rats. PLoS One. 2013;8:e58730.PubMedPubMed CentralView ArticleGoogle Scholar
  318. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP Kinase activity in human aortic smooth muscle cells. Hypertension. 1999;33:177–82.PubMedView ArticleGoogle Scholar
  319. Liu S, Wang L, Wang W, Lin J, Han J, Sun H, et al. TSC-36/FRP inhibits vascular smooth muscle cell proliferation and migration. Exp Mol Pathol. 2006;80:132–40.PubMedView ArticleGoogle Scholar
  320. Pan W, Ikeda K, Takebe M, Yamori Y. Genistein, Daidzein and Glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Nutr. 2001;131:1154–8.PubMedGoogle Scholar
  321. García MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie. 2007;89:799–811.PubMedView ArticleGoogle Scholar
  322. Handy I, Patel RC. STAT1 requirement for PKR-induced cell cycle arrest in vascular smooth muscle cells in response to heparin. Gene. 2013;524:15–21.PubMedView ArticleGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement